Extracellular vesicles for macrophage reprogramming: an emerging paradigm in immunomodulatory therapeutics Authors: Ha Young Jo, Min Kyeong Kim, Kyeong Tae Kim, Chanwoo Choi, Won Jong Rhee Published: 2025 ABSTRACT Macrophages are pivotal regulators of immunity, and due to their ability to differentiate into either pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes with remarkable plasticity, they can be used as strategies for treating diseases ranging from cancer to chronic inflammatory conditions. However, despite extensive research, the mechanisms driving macrophage polarization and the role of extracellular vesicles (EVs) in regulating these processes remain not fully understood. In particular, the specific signaling pathways and clinical applications of EV-mediated macrophage reprogramming are still under active investigation. Many recent studies have shown that EVs alter the immune environment by reprogramming macrophages to transition between M1 and M2 polarized states, thereby exhibiting therapeutic activity in a variety of diseases, including cancer. In addition, EV engineering aimed at improving macrophage reprogramming capabilities has been shown to enhance therapeutic efficacy, providing unprecedented opportunities to overcome previously untreatable diseases. This review addresses ongoing challenges by examining the latest findings on EV-mediated macrophage reprogramming and highlighting gaps in our understanding of the signaling mechanisms and clinical applications. We explore the signaling pathways and therapeutic potential of EVs in macrophage phenotyping, analyze evidence from disease models, and discuss how EV engineering strategies, including cargo loading and surface modification, expand their clinical use. Additionally, we consider critical factors for clinical translation, such as standardized production, immunogenicity, and safety. Overall, this review emphasizes the potential of EV-mediated macrophage reprogramming as a promising therapeutic strategy for immune-related diseases, while also addressing challenges and future directions for clinical application.Graphical Abstract Introduction Extracellular vesicle biogenesis EVs are nanovesicles secreted by cells and enclosed by a phospholipid bilayer. All references have been validated because more unstructured references were receivedThey are classified into exosomes, microvesicles (MVs), and apoptotic bodies (ABs) based on their biosynthetic mechanisms (Fig. 1) [1]. Exosomes are formed as early endosomes based on endosomal trafficking within the cell, mature into multivesicular bodies (MVBs), and generate intraluminal vesicles (ILVs) through inward budding at the plasma membrane [2]. ILV formation is mainly mediated by the Endosomal Sorting Complex Required for Transport (ESCRT) complex. MVBs fuse with the plasma membrane through the action of Rab GTPases, and the ILVs are released into the extracellular space and function as exosomes [3, 4]. Fig. 1Biogenesis, composition, and immunological functions of extracellular vesicles. MVB, multivesicular bodies; ILV, intraluminal vesicles; ESCRT, endosomal sorting complex required for transport; ARF6, ADP-ribosylation factor 6; MLCK, myosin light chain kinase; CD, cluster of differentiation; MHC-I/II, major histocompatibility complex class I and II; ICAM-1, Intercellular Adhesion Molecule-1; IFN-γ, Interferon-γ; THBS1, thrombospondin-1; HMGB1, high mobility group box 1; iNOS, inducible nitric oxide synthase; AEA, anandamide; PA, phosphatidic acid; PC, phosphatidylcholine; PI, phosphatidylinositols; PS, phosphatidylserine Biogenesis, composition, and immunological functions of extracellular vesicles. MVB, multivesicular bodies; ILV, intraluminal vesicles; ESCRT, endosomal sorting complex required for transport; ARF6, ADP-ribosylation factor 6; MLCK, myosin light chain kinase; CD, cluster of differentiation; MHC-I/II, major histocompatibility complex class I and II; ICAM-1, Intercellular Adhesion Molecule-1; IFN-γ, Interferon-γ; THBS1, thrombospondin-1; HMGB1, high mobility group box 1; iNOS, inducible nitric oxide synthase; AEA, anandamide; PA, phosphatidic acid; PC, phosphatidylcholine; PI, phosphatidylinositols; PS, phosphatidylserine MVs are formed directly from the plasma membrane through the breakdown of membrane phospholipid asymmetry and cytoskeletal rearrangement [5]. Phosphatidylserine (PS) is exposed to the outer surface of the plasma membrane [6], and ARF6 activation activates the phospholipase D-ERK-MLCK signaling pathway, leading to the phosphorylation of myosin light chain [5, 7]. Subsequently, the ESCRT components mediate membrane fission and release mature MVs into the extracellular space [8]. During this process, MVs selectively encapsulate the membrane proteins that perform biological functions [9, 10]. ABs are vesicles produced in the late stages of apoptosis and contain cellular components such as organelles and fragmented DNA. Unlike exosomes and MVs, they are produced during apoptosis and are rapidly cleared by phagocytes [11–13]. Accordingly, EVs are formed through distinct mechanisms mediated by specific intracellular pathways and regulatory factors. These biogenesis pathways serve as critical determinants of their molecular composition, interactions with recipient cells, and physiological and pathological functions [14]. Biomolecular composition and immunological function of extracellular vesicles EVs inherit properties from their parent cells and contain a variety of biomolecules, such as proteins, lipids, nucleic acids, and metabolites. Therefore, cells that receive them undergo diverse biological changes (Fig. 1) [15]. EVs commonly contain proteins involved in the ESCRT pathway and the tetraspanin family of proteins [16–20]. They also carry various proteins that contribute to the functional transport of EVs [21–23]. EVs encapsulate a variety of nucleic acids, such as DNA, messenger RNA (mRNA), microRNA (miRNA), and long noncoding RNA (lncRNA), which are inherited from their parent cells. They contribute to intercellular communication by delivering various nucleic acids into cells and mediating biological functions such as gene expression regulation, cell signaling, and inflammatory response regulation [24, 25]. EVs possess a phospholipid bilayer structure that protects proteins and nucleic acids [26]. The lipids contained in EVs not only maintain structural stability, but also structure formation and fluidity, and aid in EV transport [27–29]. Furthermore, they are involved in signal transduction and contribute to intercellular communication [30]. Certain EVs possess unique biomolecules that exhibit specific functions and effectively contribute to the immune response (Table 1). For example, EV receptors promote antigen presentation, and T cell differentiation and activation [31–33]. Specifically, T cells and macrophages closely interact with each other to shape the immune microenvironment. Therefore, the immunological functions of EVs can indirectly modulate macrophage activity. Activated T cells regulate macrophage polarization, while macrophage phenotypes, in turn, influence T cell functions to maintain immune balance [34, 35]. These reciprocal interactions regulate the phenotypes of both macrophages and T cells within the immune system, highlighting that macrophage reprogramming can critically influence immune homeostasis. Among them, certain EVs carry bioactive molecules capable of not only suppressing tumor progression, regulating T cells, and promoting neuroprotection but also reprogramming macrophages, thereby modulating the immune microenvironment [36–39]. Therefore, biomolecules contained in EVs perform various functions in the immune environment, the details of which are summarized in Fig. 1; Table 1. Table 1Immunomodulatory constituents of extracellular vesiclesMolecular ComponentMoleculeCategoryFunctionRef.ProteinMHC-I/II, IL-15Rαmembrane protein- Antigen presentation and T cell differentiation and activation[31–33]CD86, ICAM1- Promotion of immune cell interaction and activation[40]NKp30, NKp46- Promotion of tumor cell killing[41, 42]CD73membrane protein- Macrophage reprogramming[43–45]CD5LSecreted protein[39]iNOSenzyme- Macrophage reprogramming[44]IFN-γCytokine[45]THBS1glycoprotein[46]HMGB-1Nuclear protein[47]Nucleic acidmitochondrial DNADNA- Tumor suppression[39]HOTTIP, HOTAIR, H19lncRNA- Macrophage reprogramming[48, 49]miR-21, miR-155miRNA- Regulation of immune responses[36, 50]miR-765, miR-25-3p, miR-155-5p, miR-215-5p, miR-375- Tumor suppression[38, 51]let-7d, miR-142-3p, miR-150-5p- Suppression of T cell proliferation[37, 52, 53]miR-26, miR-146a, miR-223- Macrophage reprogramming[36, 54, 55]LipidAEAEndocannabinoids- Immunosuppression and neuroprotection[56] Table 1Immunomodulatory constituents of extracellular vesiclesMolecular ComponentMoleculeCategoryFunctionRef.ProteinMHC-I/II, IL-15Rαmembrane protein- Antigen presentation and T cell differentiation and activation[31–33]CD86, ICAM1- Promotion of immune cell interaction and activation[40]NKp30, NKp46- Promotion of tumor cell killing[41, 42]CD73membrane protein- Macrophage reprogramming[43–45]CD5LSecreted protein[39]iNOSenzyme- Macrophage reprogramming[44]IFN-γCytokine[45]THBS1glycoprotein[46]HMGB-1Nuclear protein[47]Nucleic acidmitochondrial DNADNA- Tumor suppression[39]HOTTIP, HOTAIR, H19lncRNA- Macrophage reprogramming[48, 49]miR-21, miR-155miRNA- Regulation of immune responses[36, 50]miR-765, miR-25-3p, miR-155-5p, miR-215-5p, miR-375- Tumor suppression[38, 51]let-7d, miR-142-3p, miR-150-5p- Suppression of T cell proliferation[37, 52, 53]miR-26, miR-146a, miR-223- Macrophage reprogramming[36, 54, 55]LipidAEAEndocannabinoids- Immunosuppression and neuroprotection[56] Immunomodulatory constituents of extracellular vesicles In conclusion, EVs are recognized as natural components of the body that possess high biocompatibility and cell-to-cell communication capabilities [2, 25, 57]. Notably, they contain a variety of biomolecules and certain components are known to be involved in immune regulation. This suggests that EVs can perform various biological functions as nanovesicles with minimal side effects in the immune environment, thereby improving the immune system. Functional diversity of polarized macrophages The immune system plays a critical role in maintaining the internal homeostasis and defending the host against exogenous pathogens. Composed of both innate and adaptive immunity, it interacts with a network of immune cells and molecular signals to orchestrate complex and finely regulated immune responses. Among them, macrophages, dendritic cells, natural killer cells, T lymphocytes, and B lymphocytes serve as central regulators of the immune response [58, 59]. Macrophages are key components of the innate immune system that contribute to pathogen clearance and tissue repair [60]. Macrophage can differentiate into distinct functional states in response to various stimuli in the microenvironment, such as cytokines, microbial products, and growth factors. They are typically divided into two major phenotypes with different functions. The M1 phenotype refers to classically activated macrophages, whereas the M2 phenotype represents alternatively activated macrophages [61, 62]. M1 macrophages are pro-inflammatory macrophages that contribute to immune defense by eliminating pathogens, suppressing tumor growth, and initiating early immune responses [60, 63]. M1 macrophages are induced by microbial components and cytokines, such as lipopolysaccharide (LPS) and IFN-γ. They secrete pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-12 (IL-12). Additionally, M1 macrophages produce reactive oxygen species (ROS) and reactive nitrogen species to induce antipathogenic and anti-tumor responses [64–66], and their enhanced antigen-presenting ability contributes to the promotion of Th1-type immune responses. Therefore, M1 macrophages play a crucial role in host defense and early immune responses [67, 68]. M2 macrophages are activated anti-inflammatory phenotypes that play essential roles in resolving inflammation, promoting tissue repair, and facilitating fibrosis. This process contributes to the maintenance of tissue homeostasis. M2 phenotype is induced by Th2-associated cytokines such as interleukin-4 (IL-4) and interleukin-13 (IL-13), and is characterized by the secretion of anti-inflammatory mediators including interleukin-10 (IL-10) and transforming growth factor-β (TGF-β), which suppress immune activation and enhance tissue regeneration [69–71]. However, some studies have shown that M2 macrophages promote tumor growth and metastasis by creating an immunosuppressive tumor microenvironment. Therefore, while M2 macrophages may function in anti-inflammation and maintaining tissue homeostasis, they also have the potential to contribute to disease progression [71–73]. Macrophage polarization is closely linked to the regulation of inflammatory responses and is therefore a key process in determining disease progression in various pathological settings. In particular, EVs contain various biomolecules that can deliver substances to macrophages, making them effective carriers for inducing the transition from M1 to M2 macrophages [74]. Therefore, macrophage reprogramming using EVs is a promising therapeutic strategy in immune environments. Notably, in recent years, EV-based reprogramming approaches have rapidly expanded in both preclinical and clinical research across diverse disease models, including cancer, infectious, and inflammatory disorders. While these strategies show substantial promise, most clinical applications remain at an early stage and many technical, standardization, and mechanistic challenges persist. Thus, understanding and advancing EV-mediated macrophage reprogramming is a rapidly evolving field with considerable translational potential, but one that still requires significant progress before widespread clinical adoption. Extracellular vesicle–mediated macrophage reprogramming for immunotherapy Macrophage reprogramming as a biodirectional therapeutic strategy Macrophage phenotypes are involved in the treatment of various immune-related diseases such as inflammatory diseases, infectious diseases, cancer, and neurodegenerative diseases. Therefore, strategies to differentiate and polarize existing macrophages toward a desired phenotype would be effective in improving disease outcomes [75, 76]. For example, in chronic inflammatory diseases such as rheumatoid arthritis and atherosclerosis, M1 macrophages contribute to persistent inflammatory responses and tissue damage. In these cases, reprogramming macrophages from the M1 phenotype to the M2 phenotype can suppress inflammatory responses and promote tissue repair, resulting in therapeutic effects [77–79]. Conversely, tumor-associated macrophages (TAMs) in the tumor microenvironment are primarily composed of M2 macrophages that support tumor growth and induce immune evasion. In these environments, reprogramming M2 macrophages to M1 macrophages can enhance the anti-tumor immune response and improve the outcome [80–83]. Furthermore, reprogramming is expected to be effective in neurodegenerative diseases involving microglia in the central nervous system, such as Alzheimer’s and Parkinson’s disease. The misactivation of microglia directly contributes to neuronal cell death and disease progression by inducing chronic neuroinflammation. Notably, recent studies demonstrate that exosomal miRNAs play a critical role in modulating microglial polarization in these neuroinflammatory contexts. For example, miR-124 and miR-146a promote M2-like phenotypes by regulating TLR4 and IL-10 signaling pathways, whereas miR-155 drives M1-like polarization through RAGE–NF-κB pathway activation [84, 85]. These dynamic regulatory mechanisms facilitate transitions between Iba1⁺/CD206⁺ (M2-like) and Iba1⁺/CD32⁺ (M1-like) microglial subtypes, which are essential for maintaining the balance between neuroinflammatory and reparative processes within the CNS. Additionally, hypoxia-derived exosomes (Hypo-Exo) enriched with LncGm3749 have been shown to promote microglial reprogramming from M1 to M2 by activating PPARγ and inhibiting miR-130b-3p, offering novel therapeutic perspectives [86, 87]. Changing the M1 phenotype, which secretes excessive inflammatory mediators and induces neuronal cell death and synaptic dysfunction [88], to the M2 phenotype, which promotes tissue regeneration and recovery of damaged neurons, is crucial for therapeutic intervention. Reprogramming microglia from the M1 phenotype to the M2 phenotype is considered a promising therapeutic strategy for attenuating the progression of neurodegenerative diseases [89–91]. The desired phenotype of macrophages or microglia may vary depending on the type of disease and the underlying pathophysiology. In chronic inflammatory diseases, the induction of the anti-inflammatory M2 phenotype may be favorable, whereas in cancer or infectious diseases, promoting the pro-inflammatory M1 phenotype may be more appropriate. Therefore, careful consideration of disease-specific characteristics and the surrounding microenvironment is essential when designing macrophage reprogramming strategies [75, 76]. Recent studies have highlighted T cell–derived and dendritic cell–derived EVs as promising candidates for immunotherapy [33, 51]. Despite these advances, macrophage reprogramming offers distinct therapeutic advantages that complement T cell- and dendritic cell-mediated immune regulation. Through macrophage reprogramming, it is possible to elicit a rapid immune response and restore immune cell populations. Also, recent studies have shown that EVs can directly affect macrophages, inducing reprogramming between the pro-inflammatory M1 and anti-inflammatory M2 phenotypes, but also participate in broader regulatory mechanisms. This has led to a rapid expansion of research using EVs to regulate macrophage polarization. To date, EVs derived from various cell types have been reported to function as mediators of intercellular delivery capable of modulating macrophage phenotypes across multiple pathological conditions, highlighting their potential as therapeutic agents [74, 92]. Therefore, it is essential to clarify the underlying regulatory mechanisms and evaluate the therapeutic effects of EV-mediated macrophage reprogramming in order to develop treatments applicable to a wide range of diseases. Reprogramming M1 to M2: promoting inflammation resolution and tissue repair Reprogramming of macrophages from M1 to M2 has been reported to exhibit therapeutic effects in various disease environments associated with chronic inflammation, tissue damage, or immune imbalance. In particular, EVs, which are derived from various cells, function as intercellular delivery mediators capable of inducing macrophage phenotype modulation in various diseases, thereby drawing attention to their therapeutic potential. The immunomodulatory function serves as the basis for the involvement of various cell-derived EVs, such as M2 macrophages, mesenchymal stem cells (MSCs), inflammatory-stimulated bone marrow mesenchymal stem cells (iBMSC), and embryonic stem cell-derived mesenchymal stem cells (ESC-MSCs), in macrophage reprogramming. Studies have reported how each type of EV induces macrophage phenotype switching in different disease environments. M2 macrophage-derived extracellular vesicles M2 macrophages are the key immune cells that contribute to immune homeostasis. They do this by secreting anti-inflammatory and tissue-regenerative factors, such as IL-10, TGF-β, and arginase-1 (Arg-1), and by interacting with various cell types. These functions are partially mediated by EVs. In particular, M2 macrophage-derived extracellular vesicles (M2EV) contain immunoregulatory molecules with anti-inflammatory properties, making them a promising strategy for inducing macrophage polarization from the M1 to M2 phenotype (Fig. 2; Table 2). Fig. 2Macrophage reprogramming mediated by extracellular vesicles and their disease-specific therapeutic implications. Reprogramming of macrophages into pro-inflammatory M1 or anti-inflammatory M2 phenotypes in response to bioactive cargos delivered by diverse types of EVs. Influence of this reprogramming on disease progression, with either therapeutic improvement or pathological exacerbation depending on the disease context. The diseases in the blue boxes are associated with therapeutic improvement, whereas those in the red boxes are associated with pathological exacerbation. MSCs, mesenchymal stem cell; HNSCC, head and neck squamous cell carcinoma; ALI, acute lung injury; OA, osteoarthritis; RA, rheumatoid arthritis; IBD, Inflammatory bowel disease Macrophage reprogramming mediated by extracellular vesicles and their disease-specific therapeutic implications. Reprogramming of macrophages into pro-inflammatory M1 or anti-inflammatory M2 phenotypes in response to bioactive cargos delivered by diverse types of EVs. Influence of this reprogramming on disease progression, with either therapeutic improvement or pathological exacerbation depending on the disease context. The diseases in the blue boxes are associated with therapeutic improvement, whereas those in the red boxes are associated with pathological exacerbation. MSCs, mesenchymal stem cell; HNSCC, head and neck squamous cell carcinoma; ALI, acute lung injury; OA, osteoarthritis; RA, rheumatoid arthritis; IBD, Inflammatory bowel disease Table 2Extracellular vesicle-mediated macrophage reprogramming: signaling pathways and therapeutic implicationsDirection of macrophage reprogrammingEV sourcecomponentsTargeted macrophage cell typepolarization mechanism(pathway)DiseaseEffectRef.M2M2 macrophagesProtein MMP19, CCL8Synovial macrophagesRheumatoid arthritis- Suppression of joint swelling- Reduction of synovial inflammation- Attenuation of bone erosion and articular cartilage damage [93]miR-21, miR-124, miR-26THP-1 cell-derived macrophageschemokine signaling pathwaysviral myocarditis- Promotion of local myocardial immune regulation- Inhibition of inflammatory reactions Enhancement of cardiac repair [36]Protein Tnf, Ccl5, Cxcl2, Ptgs2, Icam1, Traf1, Cd40, and Ccl4Raw264.7 cell-derived macrophagesNOD-like receptor, TNF, NF-κB, and Toll-like receptor signaling pathwaysOsteoarthritis- Mitigation of synovitis- Reduction of cartilage degradation- Alleviation of subchondral bone damage- Improvement of gait abnormalities [94]miR-21-5pBMDMOsteoarthritis- Anti-inflammatory effect- Reduction of chondrocyte apoptosis [95]MSCsmiR-223, miR-146b, miR-126, miR-199aBMDMSkeletal muscle injury- tissue repair- suppression of inflammation- promotion of muscle regeneration [55]iBMSCRpl14 geneBMDMOsteoarthritis- Promotion of chondrocyte proliferation- Inhibition of extracellular matrix degradation- Alleviation of osteoarthritis symptoms [96]ESC-MSCsmiR-21, miR-320a, miR-423, miR-100, and miR-26aTHP-1 cell-derived macrophagesNF-kBm JAK/STAT, PI3K/AKTAcute compartment syndrome- Anti-inflammatory effect- Promotion of angiogenesis- Restoration of muscle function [97]GMSCCD73, CD5LTHP-1 cell-derived macrophagesmTOR, HIF-1a signaling pathway- Promotion of M1-to-M2 macrophage repolarization [43]Laminar Shear Stress-stimulated endothelial cellsmiR-34c-5pRaw264.7 cell-derived macrophages, BMDMTGF-B-Smad3 signaling pathwayAtherosclerosis- improvement of the immune microenvironment of atherosclerotic lesions- plaque stabilization [98]MDA-MB-231-conditioned HUVECs4T1-conditioned MS1 cellsmiR-142-5p,183-5p, 222-3pRaw264.7 cell-derived macrophagesGlioma, IL-3, ErbB signaling pathwayTumor- Promotion of tumor growth [99]Cardiosphere-derived cellsmiR-146aBMDMMyocardial infarction- Anti-inflammatory effect- Promotion of angiogenesis [100]Human adipose tissueRaw264.7 cell-derived macrophagesFull-thickness skin wound- promotion of tissue repair [101]M1M1 macrophagesmiR-155, miR30b/3Raw264.7 cell-derived macrophagesBrest cancer- Tumor suppression- Improvement of TME [50]Raw264.7 cell-derived macrophagesBrest cancer- Tumor suppression and metastasis [102]miR340-5p, Let-7f, HOTAIR, H19Raw264.7 cell-derived macrophages [48]Raw264.7 cell-derived macrophagesColorectal carcinoma- Tumor suppression and reduction [103]lncRNA HOTTIPTHP-1 cell-derived macrophages- Competitive binding with miR-19a-3p / miR-19b-3p- Activation of the TLR5/NF-κB signaling pathwayHead and neck squamous cell carcinoma- promotion of an anti-tumor environment [49]iNOSRaw264.7 cell-derived macrophages- Induction of nitric oxide production via iNOScolorectal carcinoma- Antitumor effect [44]Raw264.7 cell-derived macrophages- Activation of the TLR4/NF-κB signaling pathway [104]miR-155-5plung tissues-derived macrophages- Activation of the p38/MAPK signaling pathwaySepsis-associated acute lung injury- Induction of tissue damage- decrease in lung injury and inflammation [105]Bone marrow-derived macrophagesmiR-27a, miR-125b, miR-155, miR-199aBMDM, human TAMColorectal carcinoma, brest cancer- potentiation of antitumor immunity surrounding the tumor [106]BMDM- Efficient downregulation of NF-κB p50 and ROCK expressionBrest cancer- inhibition of tumor growth [107]L-PRPTHP-1 cell-derived macrophages- induction of macrophage apoptosis and NO productionChronic refractory wound- Chronic wound healing [108]activated CD4 + T cellIFN-γTHP-1 cell-derived macrophages, BMDM- activation of the stimulator of interferon genesCancer- disruption of the immune suppressive environment [45]OSCC cellTHBS1THP-1 cell-derived macrophages, PBMCs- Activation of p38 MAPK, Akt, and SAPK/JNKOral squamous cell carcinoma- Enhanced tumorigenesis [46]Colorectal cancer cellmiR-21, miR-21-5pkupffer cell-derived macrophages- Activation of TLR7liver metastasis- Enhanced metastasis and macrophage infiltration- Induction of an inflammatory microenvironment [109]HPV + HNSCC cellmiR-9THP-1 cell-derived macrophages-Suppression of PPARγHead and neck squamous cell carcinoma- Improved efficacy of radiotherapy [110]TumorHMGB-1Peritoneal macrophages- Activation of NF-κB via the TLR2/MyD88 signaling pathwayCancer- Induction of immunosuppressive macrophages [47]miR-214Raw264.7 cell-derived macrophages- Activation of NF-κBMelanoma- Induction of tumor metastasis [111]BMEC (OGD cultured)miR-3613-3pHMC3 cells-derived microglia- Binding of CH3H1 protein to the 3’-UTR- Inhibition of protein expressionStroke- Decreased neuronal cell viability [112] Table 2Extracellular vesicle-mediated macrophage reprogramming: signaling pathways and therapeutic implicationsDirection of macrophage reprogrammingEV sourcecomponentsTargeted macrophage cell typepolarization mechanism(pathway)DiseaseEffectRef.M2M2 macrophagesProtein MMP19, CCL8Synovial macrophagesRheumatoid arthritis- Suppression of joint swelling- Reduction of synovial inflammation- Attenuation of bone erosion and articular cartilage damage [93]miR-21, miR-124, miR-26THP-1 cell-derived macrophageschemokine signaling pathwaysviral myocarditis- Promotion of local myocardial immune regulation- Inhibition of inflammatory reactions Enhancement of cardiac repair [36]Protein Tnf, Ccl5, Cxcl2, Ptgs2, Icam1, Traf1, Cd40, and Ccl4Raw264.7 cell-derived macrophagesNOD-like receptor, TNF, NF-κB, and Toll-like receptor signaling pathwaysOsteoarthritis- Mitigation of synovitis- Reduction of cartilage degradation- Alleviation of subchondral bone damage- Improvement of gait abnormalities [94]miR-21-5pBMDMOsteoarthritis- Anti-inflammatory effect- Reduction of chondrocyte apoptosis [95]MSCsmiR-223, miR-146b, miR-126, miR-199aBMDMSkeletal muscle injury- tissue repair- suppression of inflammation- promotion of muscle regeneration [55]iBMSCRpl14 geneBMDMOsteoarthritis- Promotion of chondrocyte proliferation- Inhibition of extracellular matrix degradation- Alleviation of osteoarthritis symptoms [96]ESC-MSCsmiR-21, miR-320a, miR-423, miR-100, and miR-26aTHP-1 cell-derived macrophagesNF-kBm JAK/STAT, PI3K/AKTAcute compartment syndrome- Anti-inflammatory effect- Promotion of angiogenesis- Restoration of muscle function [97]GMSCCD73, CD5LTHP-1 cell-derived macrophagesmTOR, HIF-1a signaling pathway- Promotion of M1-to-M2 macrophage repolarization [43]Laminar Shear Stress-stimulated endothelial cellsmiR-34c-5pRaw264.7 cell-derived macrophages, BMDMTGF-B-Smad3 signaling pathwayAtherosclerosis- improvement of the immune microenvironment of atherosclerotic lesions- plaque stabilization [98]MDA-MB-231-conditioned HUVECs4T1-conditioned MS1 cellsmiR-142-5p,183-5p, 222-3pRaw264.7 cell-derived macrophagesGlioma, IL-3, ErbB signaling pathwayTumor- Promotion of tumor growth [99]Cardiosphere-derived cellsmiR-146aBMDMMyocardial infarction- Anti-inflammatory effect- Promotion of angiogenesis [100]Human adipose tissueRaw264.7 cell-derived macrophagesFull-thickness skin wound- promotion of tissue repair [101]M1M1 macrophagesmiR-155, miR30b/3Raw264.7 cell-derived macrophagesBrest cancer- Tumor suppression- Improvement of TME [50]Raw264.7 cell-derived macrophagesBrest cancer- Tumor suppression and metastasis [102]miR340-5p, Let-7f, HOTAIR, H19Raw264.7 cell-derived macrophages [48]Raw264.7 cell-derived macrophagesColorectal carcinoma- Tumor suppression and reduction [103]lncRNA HOTTIPTHP-1 cell-derived macrophages- Competitive binding with miR-19a-3p / miR-19b-3p- Activation of the TLR5/NF-κB signaling pathwayHead and neck squamous cell carcinoma- promotion of an anti-tumor environment [49]iNOSRaw264.7 cell-derived macrophages- Induction of nitric oxide production via iNOScolorectal carcinoma- Antitumor effect [44]Raw264.7 cell-derived macrophages- Activation of the TLR4/NF-κB signaling pathway [104]miR-155-5plung tissues-derived macrophages- Activation of the p38/MAPK signaling pathwaySepsis-associated acute lung injury- Induction of tissue damage- decrease in lung injury and inflammation [105]Bone marrow-derived macrophagesmiR-27a, miR-125b, miR-155, miR-199aBMDM, human TAMColorectal carcinoma, brest cancer- potentiation of antitumor immunity surrounding the tumor [106]BMDM- Efficient downregulation of NF-κB p50 and ROCK expressionBrest cancer- inhibition of tumor growth [107]L-PRPTHP-1 cell-derived macrophages- induction of macrophage apoptosis and NO productionChronic refractory wound- Chronic wound healing [108]activated CD4 + T cellIFN-γTHP-1 cell-derived macrophages, BMDM- activation of the stimulator of interferon genesCancer- disruption of the immune suppressive environment [45]OSCC cellTHBS1THP-1 cell-derived macrophages, PBMCs- Activation of p38 MAPK, Akt, and SAPK/JNKOral squamous cell carcinoma- Enhanced tumorigenesis [46]Colorectal cancer cellmiR-21, miR-21-5pkupffer cell-derived macrophages- Activation of TLR7liver metastasis- Enhanced metastasis and macrophage infiltration- Induction of an inflammatory microenvironment [109]HPV + HNSCC cellmiR-9THP-1 cell-derived macrophages-Suppression of PPARγHead and neck squamous cell carcinoma- Improved efficacy of radiotherapy [110]TumorHMGB-1Peritoneal macrophages- Activation of NF-κB via the TLR2/MyD88 signaling pathwayCancer- Induction of immunosuppressive macrophages [47]miR-214Raw264.7 cell-derived macrophages- Activation of NF-κBMelanoma- Induction of tumor metastasis [111]BMEC (OGD cultured)miR-3613-3pHMC3 cells-derived microglia- Binding of CH3H1 protein to the 3’-UTR- Inhibition of protein expressionStroke- Decreased neuronal cell viability [112] Extracellular vesicle-mediated macrophage reprogramming: signaling pathways and therapeutic implications - Suppression of joint swelling - Reduction of synovial inflammation - Attenuation of bone erosion and articular cartilage damage - Promotion of local myocardial immune regulation - Inhibition of inflammatory reactions Enhancement of cardiac repair - Mitigation of synovitis - Reduction of cartilage degradation - Alleviation of subchondral bone damage - Improvement of gait abnormalities - Anti-inflammatory effect - Reduction of chondrocyte apoptosis - tissue repair - suppression of inflammation - promotion of muscle regeneration - Promotion of chondrocyte proliferation - Inhibition of extracellular matrix degradation - Alleviation of osteoarthritis symptoms - Anti-inflammatory effect - Promotion of angiogenesis - Restoration of muscle function - improvement of the immune microenvironment of atherosclerotic lesions - plaque stabilization MDA-MB-231-conditioned HUVECs 4T1-conditioned MS1 cells - Anti-inflammatory effect - Promotion of angiogenesis - Tumor suppression - Improvement of TME - Competitive binding with miR-19a-3p / miR-19b-3p - Activation of the TLR5/NF-κB signaling pathway - Induction of tissue damage - decrease in lung injury and inflammation - Enhanced metastasis and macrophage infiltration - Induction of an inflammatory microenvironment - Binding of CH3H1 protein to the 3’-UTR - Inhibition of protein expression M2EV are enriched with proteins involved in the generation and migration of M2 macrophages, as well as key factors related to macrophage reprogramming, and reprogram M1 macrophages into the M2 phenotype with an efficiency exceeding 90%. In a rheumatoid arthritis model, M2EV downregulated the expression of M1 markers such as iNOS and TNF-α, while simultaneously upregulating M2 markers including Arg-1 and IL-10, thereby rapidly shifting the phenotype of synovial macrophages. These reprogrammed M2 macrophages alleviate the symptoms by suppressing cartilage damage and joint swelling. Therefore, intra-articular administration of M2EV effectively converted the phenotype of synovial macrophages, inhibited cartilage destruction and joint inflammation, and ultimately relieved symptoms of rheumatoid arthritis [93]. Another study found that M2 macrophage–derived ABs (M2-ABs) were enriched with immunoregulatory miRNAs, such as miR-21a-5p, miR-29a-3p, let-7c-5p, and miR-223-3p. These M2-ABs suppressed iNOS expression in M1 macrophages while increasing the expression of Arg-1 and CD206, thereby promoting a phenotypic switch to M2 macrophages. Inhibition of miR-21a-5p reduced reprogramming efficiency to 46.5%, demonstrating the role of these miRNAs in macrophage polarization. Consistent with these findings, M2-ABs alleviated inflammation and protected against cartilage damage in an osteoarthritis model [95]. Another study utilizing the same type of EVs demonstrated their regulatory effects on macrophages. These M2EV contained multiple non-coding RNAs involved in macrophage polarization, including miR-21, miR-124, and miR-26. When applied to M1 macrophages, EVs suppress inducible nitric oxide synthase (iNOS) expression and increase CD206 expression, thereby promoting a phenotypic switch to M2 macrophages. The proportion of M1 macrophages was reduced, whereas the proportion of M2 macrophages increased, thereby improving the inflammatory microenvironment and attenuating the pathological progression of valvular macrophage-associated diseases through anti-inflammatory effects [36]. Furthermore, in an osteoarthritis model, M2EV were shown to suppress the expression of iNOS, IL-6, TNF-α, and matrix metalloproteinase-13, while upregulating the expression of aggrecan, type II collagen (COL2), and CD206, thereby protecting the cartilage matrix by preserving chondrocytes and alleviating inflammation [58]. In conclusion, M2EV exerts anti-inflammatory effects through M1 to M2 reprogramming. In most reported studies, miRNAs have been identified as major regulatory factors. However, the precise molecular mechanisms and the relative contribution of each component remain unclear. In addition, disease-specific mechanistic differences have not been sufficiently investigated. Therefore, further studies directly comparing the molecular characteristics of M2EV are needed to clarify their underlying mechanisms. Mesenchymal stem cells-derived extracellular vesicles Recently, EVs secreted by MSCs derived from various tissues have attracted attention as immunoregulatory factors capable of inducing macrophage polarization (Fig. 2; Table 2). MSC-derived EVs differ in their cargo composition, including miRNAs, proteins, and metabolites, depending on the tissue of origin, which can result in different mechanisms of macrophage reprogramming and distinct physiological effects. MSC-derived EVHypo contains miRNAs, such as miR-223, miR-146b, miR-126, and miR-199a. When applied to bone marrow-derived macrophages (BMDM), it suppressed IL-6 expression, while increasing the expression of IL-10, Arg-1, and CD206, thereby promoting a phenotypic switch from the M1 to M2 phenotype. In a skeletal muscle injury model, EVHypo simultaneously reduced M1 marker expression and increased the expression of M2 markers, paired box protein 7, myogenic differentiation 1, and embryonic myosin heavy chain (eMyhc), resulting in tissue repair and suppression of inflammation [55]. In addition, EVs derived from gingival MSCs (GMSCs) pretreated with TNF-α and interferon-α contain the proteins CD5L and CD73, which are upregulated through increased expression of inhibitor of DNA binding 3 and hypoxia-inducible factor 1-α, respectively. When applied to M1 macrophages, these EVs suppressed CD86 expression, while increasing CD206 and CD163 expression by 64.1% and 60.0%, respectively, thereby promoting M2 polarization. CD5L plays an essential role in driving phenotypic switching. Based on this mechanism, GMSC-derived EVs have demonstrated a therapeutic potential for attenuating cartilage damage through their anti-inflammatory effects [43]. Additionally, iBMSC-derived EVs suppressed the expression of ribosomal protein L14 (Rpl14) in an osteoarthritis model. This leads to increased CD206 expression and decreased iNOS and CD86 expression. This reprogramming of M1 macrophages into the M2 phenotype effectively inhibits osteoarthritis progression by preventing cartilage matrix degradation and alleviating inflammation [96]. Moreover, EVs produced from ESC-MSCs modulated the expression of phosphatase and tensin homolog (PTEN), Toll-like receptor 3, and NOD-like receptor family pyrin domain containing 3 through miRNAs such as miR-21, miR-320a, and miR-26a in an acute coronary syndrome (ACS) model. These EVs promote the reprogramming of macrophages from the M1 to M2 phenotype by suppressing the NF-κB pathway and activating the JAK-STAT and PI3K-AKT pathways. This resulted in decreased iNOS and TNF-α expression and increased IL-10, Arg-1, and CD206 expression. These changes modulate the immune environment and tissue regeneration [97]. MSC-derived EVs have been shown to facilitate M1 to M2 reprogramming. However, to utilize MSC-derived EVs from various sources more effectively, it is necessary to compare their molecular compositions to determine which MSC source is most effective for specific diseases. This will likely be essential for their clinical application. Endothelial cells–derived extracellular vesicles Endothelial cells (ECs) contribute to cellular repair and angiogenesis through miRNAs contained in EVs [113, 114] and have also been shown to reprogram M1 macrophages into M2 macrophages (Fig. 2; Table 2) [98, 115]. EVs derived from ECs exposed to laminar shear stress are enriched with miR-34c-5p, which targets the TGF-β–Smad3 signaling pathway. These EVs suppressed the expression of M1 markers, including iNOS, CD80, CD86, and TNF-α. Moreover, EVs induced the upregulation of M2 markers such as Arg-1, CD163, IL-4, and TGF-β, which promoted the repolarization of M1 macrophages to M2 macrophages. This suggests that EVs may improve the immune microenvironment of atherosclerotic lesions and contribute to plaque stabilization [98]. However, the EVs derived from ECs in the TME differed from those derived from normal ECs. EVs from human umbilical vein endothelial cells (HUVECs) co-cultured with MDA-MB-231 breast cancer cells and MS1 cells co-cultured with 4T1 cells were found to overexpress miR-142-5p, miR-183-5p, and miR-222-3p, which led to the suppression of PTEN. This effect showed an increase in Arg-1 and TGF-β expression while the levels of the M1 markers iNOS and IL-1β were maintained. Consequently, it promotes tumor growth by driving the polarization of circulating monocytes and M0 macrophages at the tumor site to the M2 phenotype [99]. Interestingly, even within the same type of endothelial cells, EVs exhibit dual functions depending on the physicochemical environment. Therefore, a precise understanding of how EV functionality changes according to interacting cell types and environmental conditions is required. Other cell–derived extracellular vesicles EVs derived from cardiosphere-derived cells are enriched in miR-146a, which induces the upregulation of Arg-1, leading to the synthesis of polyamines. This process stimulates cell proliferation and angiogenesis while decreasing nitric oxide production and reprogramming M1 macrophages into the M2 phenotype (Fig. 2; Table 2). Through their immunoregulatory and cardioprotective effects, these EVs demonstrate potential as a therapeutic strategy for myocardial infarction [100]. The tissue-specific enrichment of miR-146a reflects the cardiac regenerative capacity of the source tissue, enabling targeted applications in cardiovascular disease. Moreover, human adipose tissue-derived small extracellular vesicles (h-sEV-AT) significantly reduced the expression of M1 markers, such as IL-6 and TNF-α, while significantly increasing the expression of M2 markers, including Arg-1 and IL-10. This modulation decreases the proportion of the M1 phenotype and increases that of the M2 phenotype, leading to enhanced skin wound healing [101]. The anti-inflammatory and tissue-remodeling properties of adipose-derived EVs align with the tissue repair functions of their source tissue. EVs from different cell sources reprogram M1 to M2 macrophages via distinct mechanisms, leading to significant differences in efficiency. M2 macrophage-derived EVs employ direct delivery of anti-inflammatory miRNAs (such as miR-21a-5p, miR-29a-3p), robustly activating STAT3 or TGF-β–Smad3 pathways and typically increasing M2 marker expression (e.g., Arg-1, CD206, IL-10) 2–4 times more than context-dependent, indirect mechanisms. In contrast, EVs from other sources (like MSCs or ECs in disease settings) more often rely on indirect or environmental cues, which usually result in only modest (about 1.2–1.7-fold) increases in M2 markers and can be less consistent. Thus, direct miRNA-mediated signaling yields significantly stronger and more predictable M2 polarization than indirect or context-dependent mechanisms. Reprogramming M2 to M1: enhancing immune activation against pathologies Polarization of M1 macrophages has been reported to exert therapeutic effects by inducing a pro-inflammatory environment that suppresses and eliminates pathogens, viruses, and tumors [60, 116]. While M1 macrophages contribute to the improvement of the TME by promoting tumor control and anti-tumor responses, TAMs are predominantly composed of the M2 phenotype, which is involved in tumor proliferation, resistance to cell death, and angiogenesis [117]. Therefore, effective modulation of the TME requires reprogramming of the tumor-promoting M2 phenotype of macrophages into the M1 phenotype. M1 macrophage-derived extracellular vesicles As mentioned earlier, M1 macrophages are immune cells that contribute to host defense by secreting pro-inflammatory cytokines that play a role in immune surveillance and inflammation [118]. M1 macrophage-derived extracellular vesicles (M1EV) share the characteristics of their parent cells and display surface properties similar to those of M1 macrophages. This enables them not only to induce a pro-inflammatory environment but also to reprogram the M0 and M2 phenotypes into the M1 phenotype (Fig. 2; Table 2) [119, 120]. M1EV from RAW264.7 containing miR-155, miR-30b/30c, and cytokine-related miRNAs increase the expression of M1 markers such as iNOS and TNF-α, while decreasing the expression of M2 markers such as CD206 and IL-10. This induces reprogramming of the M2 phenotype into the M1 phenotype, leading to the suppression of 4T1 cells and improvement of the TME in breast cancer [50]. Another study reported that by upregulating the expression of M1 markers such as CD86 and MHC-II, the M2 phenotype was reprogrammed into the M1 macrophages, thereby suppressing tumor growth and metastasis [102]. Additionally, M1EV may contain miR-340-5p, Let-7f, HOTAIR, and H19, which increase the expression of M1 markers, such as iNOS and CD86, while decreasing the expression of M2 markers, such as Arg-1, CD206, and IL-10. As a result, M1EV from RAW264.7 have the potential to reprogram the M2 phenotype of macrophages into the M1 phenotype [48]. The reprogrammed M1 phenotype, with increased expression of CD86 and decreased expression of CD206 due to the influence of M1EV, demonstrated tumor suppression and elimination effects through phagocytosis of CT26 cells. In addition, in vivo evaluations showed that reprogramming suppressed and reduced tumor size, thereby increasing survival rates. Therefore, we confirmed that reprogramming is effective in colorectal carcinoma cells [103]. Furthermore, M1EV were shown to induce the reprogramming of M2 macrophages into M1 macrophages, as well as the polarization of M0 macrophages into M1 macrophages. M1EV activate the TLR4/NFκB signaling pathway, which has been reported to polarize M0 macrophages into M1 macrophages. M1EV are expected to reprogram M2 macrophages, in which the TLR4/NFκB signaling pathway is downregulated [104, 121]. In addition, iNOS present in M1EV induces macrophage reprogramming through NO production. This increases the expression of IL-6 and TNF-α, which polarizes M0 macrophages into the M1 phenotype and improves the colorectal cancer microenvironment [44, 122]. However, M1EV obtained from co-culture with hypervirulent Klebsiella pneumoniae are enriched with miR-155-5p, which downregulates mitogen- and stress-activated protein kinase 1 and activates the p38/MAPK signaling pathway. This induced reprogramming from the M2 phenotype of macrophages to the M1 phenotype and triggered acute lung injury related to sepsis, demonstrating the double-sidedness of the therapeutic effects of M1EV from RAW264.7 [105]. M1EV from THP-1 cells contain the lncRNA HOTTIP, which competitively binds to miR-19a-3p/miR-19b-3p and activate the TLR5/NF-κB pathway, increasing iNOS expression and downregulating Arg-1. This specifically induces the polarization of M0 macrophages into the M1 phenotype. Additionally, circulating monocytes increase the proportion of M1 phenotype and reduce the proportion of the M2 phenotype. These findings confirmed the possibility of treating head and neck squamous cell carcinoma (HNSCC) by promoting an anti-tumor environment [49]. M1EV from primary BMDM contain various miRNAs, including miR-27a, miR-125b, miR-155, and miR-199a. These miRNAs enhance the expression of M1 markers, such as MHC-II and CD86, and decrease the expression of the M2 marker CD206. The reprogrammed macrophages effectively contributed to tumor suppression in both colorectal and breast cancer models [106]. In another study, when BMDM-derived EVs were applied to M2 macrophages, they downregulated M2 markers such as Arg-1, TGF-β, and IL-10, while upregulating M1 markers such as IL-12 and IFN-γ. This reprogrammed M2 macrophages into the M1 phenotype, resulting in tumor reduction in a breast cancer mouse model [107]. In summary, various macrophage-derived M1EV, including RAW264.7, THP-1, and BMDM, commonly repolarize the M2 phenotype to the M1 phenotype, thereby improving the tumor environment. This suggests that M1EV are promising cancer immunotherapy agents capable of overcoming TME. Tumor cell-derived extracellular vesicles Several studies have reported that tumor cell-derived EVs can aid tumor treatment by polarizing macrophages into the M1 phenotype (Fig. 2; Table 2) [110]. Human papillomavirus (HPV)-induced HNSCC EVs, which contain miR-9, downregulated PPARδ and increased the expression of iNOS, TNF-α, and IL-6. This suggests that EVs can be effectively applied to radiotherapy in a TME environment with a specific M1/M2 polarization state by promoting polarization from the M0 to M1 phenotype [110]. However, some tumor cell-derived EVs have been reported to induce polarization of macrophages into the M1 phenotype, contributing to tumor promotion and metastasis [46, 47, 109, 111]. EVs derived from oral squamous cell carcinoma (OSCC) contain THBS1, which activates or participates in the p38, Akt, and SAPK/JNK signaling pathways. As a result, polarization from the M0 to the M1 phenotype is induced, and M1 macrophages polarized through this pathway promote tumor cell migration and contribute to TME progression [46]. Since the pathway in M2 macrophages is also suppressed, OSCC-derived EVs are expected to reprogram M2 macrophages into the M1 phenotype, thereby contributing to TME progression [123, 124]. Additionally, EVs derived from colorectal cancer cells activate TLR7 through miR-21, upregulating IL-6 and TNF-α while downregulating Arg-1 and IL-10. These EVs polarized M0 macrophages into M1 macrophages and metastasized to the liver, where they polarized Kupffer cells into the M1 phenotype. Therefore, it induced an inflammatory premetastatic niche and liver metastasis in cancer [109]. Tumor-derived EVs (tumor-derived exosomes; TDE) harbor HMGB-1, which increases NOS2 transcription and is involved in the TLR2/MyD88 pathway. Therefore, they activated NF-κB, increased PD-L1 expression, and reprogrammed M1 phenotype macrophages. Specifically, they increased the expression of iNOS and PD-L1 simultaneously upregulating the expression of Arg-1 and IL-10, which suppressed cancer metastasis, immune evasion, and T cell function, thereby promoting tumors [47]. In addition, B16F10-derived EVs adapted to an acidic environment contain miR-214, which activates the NF-κB pathway and promotes the secretion of IL-1β and TNF-α. Consequently, macrophages polarized from the M0 phenotype into the M1 phenotype weakened the connections between ECs, thereby increasing melanoma cell metastasis [111]. Most studies have demonstrated that tumor cell-derived EVs are involved in tumor growth and metastasis. However, some studies utilized tumor-derived EVs as nanocarriers by loading them with nucleic acids such as miR-33 and miR-130 [125–127]. This demonstrates the ability of certain tumor-derived EVs to polarize toward the M1 phenotype and their potential for further engineering and utilization in tumor treatment. Therefore, EVs are expected to serve as novel therapeutic strategies. Other immune cell-derived extracellular vesicles In addition, other types of EVs with cytokine and pathway modulation capabilities can reprogram macrophages to the M1 phenotype (Fig. 2; Table 2). EVs derived from leukocyte platelet-rich plasma (L-PRP) induce macrophage apoptosis and NO production, promoting the polarization of M0 phenotype macrophage into the M1 phenotype. Unlike EVs derived from pure platelet-rich plasma, which can polarize M0 macrophages into M2 macrophages, L-PRP-derived EVs stimulate abnormal immune suppression, an early pathological state in chronic refractory wounds, and contribute to reprogramming, thereby demonstrating therapeutic effects [108]. Primary activated CD4+ T cell-derived EVs, isolated from humans and mice, contain IFN-γ and can polarize M0 macrophages into the M1 phenotype through the cGAS-STING pathway by inducing the expression of M1 markers such as type I IFN and C-X-C motif chemokine ligand 10. As a result, the polarized M1 macrophages induced by EVs showed anti-tumor effects in colon adenocarcinoma, as confirmed by in vivo evaluation using the MC38 cell model [45]. In contrast, brain microvascular endothelial cell (BMEC)-derived EVs cultured in an oxygen-glucose deprived (OGD) environment harbor miR-3613-3p, which suppresses the RC3H1 protein. Consequently, they increased the expression of M1 markers, such as IL-1β and iNOS, and decreased the expression of M2 markers, such as IL-10. This induces neuronal cell death by polarizing the M2 phenotype into the M1 phenotype [128]. The strategy of reprogramming M2 macrophages into the M1 phenotype has shown great potential for improving the TME [44, 50, 106]. However, most of the current research has focused on reprogramming from the M1 phenotype to the M2 phenotype, and reprogramming from the M2 phenotype to the M1 phenotype still presents challenges in terms of recovery and stability that need to be overcome [99]. Additionally, current research on reprogramming from the M2 to the M1 phenotype has primarily focused on improving the TME, limiting its application to tumor-related tumor microenvironment-focused models. Although studies on stroke and chronic refractory wounds are ongoing, the diseases that can be targeted remain limited [45, 108, 112]. To expand its potential, further research is needed to explore therapeutic effects in a broader range of diseases by reprogramming to the M1 phenotype and targeting different disease pathways. EVs derived from various cell types reprogram M2 macrophages through different mechanisms. M1 macrophage-derived EVs primarily induce M2-to-M1 reprogramming by directly delivering inflammatory miRNAs (e.g., miR-155, miR-30b/30c), activating the NF-κB pathway and leading to a robust upregulation of M1 markers such as iNOS and TNF-α, often 2–3 times higher than other pathways. In contrast, many tumor-derived EVs rely on indirect, context-dependent mechanisms, such as TLR or stress kinase activation, which result in weaker or more variable increases in M1 markers and, in some cases, even promote tumor progression. Therefore, direct miRNA-mediated signaling tends to achieve more robust and consistent M1 polarization than indirect or context-dependent pathways. Extracellular vesicles engineering strategies for Immunomodulation Extracellular vesicles engineering strategies To date, numerous studies have demonstrated that EVs can be engineered through both endogenous and exogenous approaches for diverse therapeutic applications (Fig. 3, Table 3) [129–132]. Therapeutic efficacy can be potentiated through further engineering strategies, that suppress tumor progression, modulate the immune microenvironment, and confer targeting capabilities such as enhanced tissue penetration and the ability to traverse biological barriers, including the blood–brain barrier [133, 134]. Additionally, engineering can extend the circulation half-life of EVs or improve their pharmacokinetic profile, thereby augmenting their therapeutic potential and facilitating more effective disease treatments [135]. Fig. 3Engineering and delivery strategies of extracellular vesicles for enhanced therapeutic and immunomodulatory applications. Engineering of EVs by genetic modification, cargo loading, surface modification, and membrane fusion, with incorporation of bioactive molecules and enhancement of therapeutic potential. Integration of EVs into delivery platforms such as hydrogels, scaffolds for localized and prolonged delivery, and microneedles. Improved therapeutic outcomes across diverse disease models through combined engineering and delivery strategies Engineering and delivery strategies of extracellular vesicles for enhanced therapeutic and immunomodulatory applications. Engineering of EVs by genetic modification, cargo loading, surface modification, and membrane fusion, with incorporation of bioactive molecules and enhancement of therapeutic potential. Integration of EVs into delivery platforms such as hydrogels, scaffolds for localized and prolonged delivery, and microneedles. Improved therapeutic outcomes across diverse disease models through combined engineering and delivery strategies Table 3Extracellular vesicles engineering strategy for macrophage reprogramming and therapeutic applicationsEngineering strategyMethodEV sourceMaterialDiseaseAdditional effects and Therapeutic effectsRef.Genetic modificationNonviral transfection (electroporation)Dermal fibroblastsIL-4IL-10Acute respiratory distress syndrome- Reduction LPS-induced lung inflammation and tissue damage- Attenuation of pro-inflammatory cytokine secretion (IL-6, IL-1β, and TNF-α) and macrophage activation [136]Lentiviral transductionHuman Embryonic Kidney 293FT cellsIL-10-- Suppression of pro-inflammatory cytokine expression and NF-κB signaling activity- Preferential uptake by M1-like macrophages [137]Transduction Bacillus subtillis Cathelicidin-BFUlcerative colitis- Downregulation of IL-1β, IL-6, TNF-α and upregulation of IL-4, IL-10, TGF-β in an LPS-induced inflammatory model [138]Cell primingUltraviolet irradiationHuman umbilical cord-derived MSCsArsenic trioxideAcute graft-versus-host disease- Modulation of the inflammatory cytokine profile by downregulation of TNF-α, IL-6, IL-1β and upregulation of IL-10 and TGF-β levels [139]Laminar shear stressHuman umbilical vein endothelial cellsmiR-34c-5pAtherosclerosis- Reduction of iNOS, CD80, CD86, TNF-α and upregulation of Arg-1, CD163, IL-4, TGF-β [98, 140]Cargo loadingSonicationPeriodontal stem cellsAspirinPeriodontitis- Upregulation of IL-10 and ARG-1 expression compared to non-engineered EVs- Promotion of macrophage OXPHOS and inhibition of glycolysis [140]Passive pre-loadingRaw264.7 cellsMetforminTumor- Upregulation of TNF-α, iNOS, CD80, CD86 and downregulation of Arg-1, Mrc1, Mgl1, CD206- Significant inhibition of tumor growth, with a 41.6% and 39.9% reduction in tumor volume and weight, respectively [141]SonicationMouse peritoneal primary M2 macrophageCurcuminSpinal cord injury- Significant reduction of proinflammatory factors (TNF-α, IL-1β, IL-6) and upregulation of the anti-inflammatory factor (TGF-β) in spinal cord tissue [142]SonicationASC (tip tissue of sika deer antler)poly(I: C)Tumor- Increase in CD86⁺ cells and decrease in CD206⁺ cells in distant tumors. [143]Surface modificationNon covalent interactionASC (tip tissue of sika deer antler)M2PepTumor- Targeted delivery to M2-TAM (Tumor-associated macrophage) [143]Covalent interactionHuman placenta-derived mesenchymal stem cellsP-selectin-binding peptideAcute kidney injury- Targeted delivery to damaged endothelial cells- Downregulation of IL-6, TNF-α, and TGF-β expression accompanied by an upregulation of IL-10 expression.- Promotion of Treg accumulation in the kidneys [144]Viral transfectionHuman umbilical cord-derived MSCsCD73Spinal cord injury- Reduction in ATP levels in cerebrospinal fluid- Activation of A2bR/cAMP/PKA signaling pathway- Significant decrease in iNOS-positive cells and increase in Arg-1-positive cells in vivo [145]IncubationGingerFolic acidRheumatoid arthritis- Targeted delivery to M1 macrophages in inflamed joints- Induction of M1-to-M2 macrophage polarization via activation of the PI3K-AKT pathway [146]Covalent interactionHuman umbilical vein endothelial cellsHyaluronic acidAtherosclerosis- CD44 receptor-mediated targeting of pro-inflammatory macrophages- Significant downregulation of CD80 and IL-6 and upregulation of CD206 and IL-10 compared to non-engineered EVs [98] Table 3Extracellular vesicles engineering strategy for macrophage reprogramming and therapeutic applicationsEngineering strategyMethodEV sourceMaterialDiseaseAdditional effects and Therapeutic effectsRef.Genetic modificationNonviral transfection (electroporation)Dermal fibroblastsIL-4IL-10Acute respiratory distress syndrome- Reduction LPS-induced lung inflammation and tissue damage- Attenuation of pro-inflammatory cytokine secretion (IL-6, IL-1β, and TNF-α) and macrophage activation [136]Lentiviral transductionHuman Embryonic Kidney 293FT cellsIL-10-- Suppression of pro-inflammatory cytokine expression and NF-κB signaling activity- Preferential uptake by M1-like macrophages [137]Transduction Bacillus subtillis Cathelicidin-BFUlcerative colitis- Downregulation of IL-1β, IL-6, TNF-α and upregulation of IL-4, IL-10, TGF-β in an LPS-induced inflammatory model [138]Cell primingUltraviolet irradiationHuman umbilical cord-derived MSCsArsenic trioxideAcute graft-versus-host disease- Modulation of the inflammatory cytokine profile by downregulation of TNF-α, IL-6, IL-1β and upregulation of IL-10 and TGF-β levels [139]Laminar shear stressHuman umbilical vein endothelial cellsmiR-34c-5pAtherosclerosis- Reduction of iNOS, CD80, CD86, TNF-α and upregulation of Arg-1, CD163, IL-4, TGF-β [98, 140]Cargo loadingSonicationPeriodontal stem cellsAspirinPeriodontitis- Upregulation of IL-10 and ARG-1 expression compared to non-engineered EVs- Promotion of macrophage OXPHOS and inhibition of glycolysis [140]Passive pre-loadingRaw264.7 cellsMetforminTumor- Upregulation of TNF-α, iNOS, CD80, CD86 and downregulation of Arg-1, Mrc1, Mgl1, CD206- Significant inhibition of tumor growth, with a 41.6% and 39.9% reduction in tumor volume and weight, respectively [141]SonicationMouse peritoneal primary M2 macrophageCurcuminSpinal cord injury- Significant reduction of proinflammatory factors (TNF-α, IL-1β, IL-6) and upregulation of the anti-inflammatory factor (TGF-β) in spinal cord tissue [142]SonicationASC (tip tissue of sika deer antler)poly(I: C)Tumor- Increase in CD86⁺ cells and decrease in CD206⁺ cells in distant tumors. [143]Surface modificationNon covalent interactionASC (tip tissue of sika deer antler)M2PepTumor- Targeted delivery to M2-TAM (Tumor-associated macrophage) [143]Covalent interactionHuman placenta-derived mesenchymal stem cellsP-selectin-binding peptideAcute kidney injury- Targeted delivery to damaged endothelial cells- Downregulation of IL-6, TNF-α, and TGF-β expression accompanied by an upregulation of IL-10 expression.- Promotion of Treg accumulation in the kidneys [144]Viral transfectionHuman umbilical cord-derived MSCsCD73Spinal cord injury- Reduction in ATP levels in cerebrospinal fluid- Activation of A2bR/cAMP/PKA signaling pathway- Significant decrease in iNOS-positive cells and increase in Arg-1-positive cells in vivo [145]IncubationGingerFolic acidRheumatoid arthritis- Targeted delivery to M1 macrophages in inflamed joints- Induction of M1-to-M2 macrophage polarization via activation of the PI3K-AKT pathway [146]Covalent interactionHuman umbilical vein endothelial cellsHyaluronic acidAtherosclerosis- CD44 receptor-mediated targeting of pro-inflammatory macrophages- Significant downregulation of CD80 and IL-6 and upregulation of CD206 and IL-10 compared to non-engineered EVs [98] Extracellular vesicles engineering strategy for macrophage reprogramming and therapeutic applications IL-4 IL-10 - Reduction LPS-induced lung inflammation and tissue damage - Attenuation of pro-inflammatory cytokine secretion (IL-6, IL-1β, and TNF-α) and macrophage activation - Suppression of pro-inflammatory cytokine expression and NF-κB signaling activity - Preferential uptake by M1-like macrophages - Upregulation of IL-10 and ARG-1 expression compared to non-engineered EVs - Promotion of macrophage OXPHOS and inhibition of glycolysis - Upregulation of TNF-α, iNOS, CD80, CD86 and downregulation of Arg-1, Mrc1, Mgl1, CD206 - Significant inhibition of tumor growth, with a 41.6% and 39.9% reduction in tumor volume and weight, respectively - Targeted delivery to damaged endothelial cells - Downregulation of IL-6, TNF-α, and TGF-β expression accompanied by an upregulation of IL-10 expression. - Promotion of Treg accumulation in the kidneys - Reduction in ATP levels in cerebrospinal fluid - Activation of A2bR/cAMP/PKA signaling pathway - Significant decrease in iNOS-positive cells and increase in Arg-1-positive cells in vivo - Targeted delivery to M1 macrophages in inflamed joints - Induction of M1-to-M2 macrophage polarization via activation of the PI3K-AKT pathway - CD44 receptor-mediated targeting of pro-inflammatory macrophages - Significant downregulation of CD80 and IL-6 and upregulation of CD206 and IL-10 compared to non-engineered EVs Endogenous engineering Endogenous engineering usually involves genetic modifications. This involves the introduction of functionally active genes into cells through transfection- or transduction-based approaches using plasmids or viral vectors. This results in stable, genetically modified cell lines that can produce preengineered EVs [147]. Consistent and enhanced expression levels of functional molecules are exhibited by EVs engineered via viral transfection, while the structural integrity of EVs is preserved [148, 149]. For instance, human-induced pluripotent stem cells have been genetically modified using a lentiviral expression vector to overexpress miR-1. The resulting hiPS-miR-1ß-EVs exhibited more than a 100-fold increase in miR-1 content compared to the controls. These engineered EVs have demonstrated the ability to prevent apoptosis, reduce proliferation, and attenuate inflammatory responses in a cystic fibrosis model [150]. In another study, lentiviral transduction was employed to generate a stable adipose-derived mesenchymal stem cell (ADMSC) line overexpressing small interfering RNAs (siRNAs) targeting NF-κB, a key gene involved in skin lesion therapy. EVs derived from this engineered cell line, referred to as ADMSC-EXOs, maintained their physicochemical properties, including morphology, particle size, and membrane marker expression. These properties were similar to those observed in EVs derived from non-engineered control cells [151]. However, this approach requires a significant amount of time to establish stable cell lines and carries the potential for immunogenicity due to the use of viral vectors [152]. To address these limitations, non-viral engineering methods such as electroporation or the use of lipofectamine reagents have been explored as alternative strategies for rapid and safe modification of EVs [136, 153]. Exogenous engineering: cargo loading Exogenous engineering is a technique that functionalizes pre-isolated EVs using cargo loading, surface modification, and membrane fusion. The cargo-loading method incorporates therapeutic cargo such as small-molecule drugs, siRNAs, miRNAs, and proteins into the lumen of EVs. This enables the stable and efficient delivery of these cargoes to target cells. Passive or active loading strategies may be adopted, depending on the physicochemical properties of the cargo. Passive loading of the hydrophobic small molecule doxorubicin through co-incubation with EVs has been shown to facilitate stable cellular delivery, tumor cell apoptosis, and prolonged drug release [154, 155]. Furthermore, diffusion-based approaches using pH gradients can be employed to passively load hydrophobic drugs into EVs [156]. In contrast, active loading methods increase the membrane permeability of EVs to facilitate the incorporation of cargo such as small molecules, nucleic acids, and proteins. This is typically achieved through techniques including chemical transfection, electroporation, freeze–thaw cycles, sonication, or the use of membrane-disrupting agents such as saponins [157, 158]. Compared with passive approaches, active approaches generally yield higher loading efficiencies. For example, when curcumin was loaded into EVs, the use of saponins as an active loading method resulted in a 3-fold higher loading efficiency than the passive approach [157]. Similarly, when catalase was loaded into EVs, simple incubation achieved a loading efficiency of 4.7%, whereas freeze–thaw, sonication, and extrusion methods resulted in efficiencies of 14.7%, 26.1%, and 22.2%, respectively [159]. However, active loading techniques may compromise the structural integrity of EV membranes and potentially impair their functional stability. Therefore, careful selection of loading methods is required to balance cargo incorporation efficiency while preserving EV integrity. Exogenous engineering: surface modification Surface modification is a technique that decorates the EV surface with functional moieties such as peptides and proteins through non-covalent and covalent interactions. The EV membrane consists primarily of phospholipids, lysophospholipids, and sphingolipids, enabling the use of hydrophobic interactions and other non-covalent forces for surface engineering [159, 160]. Peptides or proteins conjugated with phospholipid-based moieties, such as 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE) can be spontaneously inserted into the lipid bilayer of EVs. Non-covalent surface modification can improve the stability and biocompatibility of EVs by introducing additional functionalities without compromising their structural or functional integrity [161, 162]. Lipidated motifs such as 1,2-distearoyl-sn-glycero-3-phosphoethanolamine–polyethylene glycol (DSPE-PEG) and 1,2-dioleoyl-sn-glycero-3-phosphocholine–polyethylene glycol (DOPC-PEG) are often utilized in PEGylation. In drug delivery systems, polyethylene glycol (PEG) forms a protective hydrophilic layer on the EV surface. This reduces the clearance by the reticuloendothelial system, improves circulation time, and decreases systemic toxicity [163]. Alternatively, covalent modification strategies enable the stable display of ligands on the EV surface via reactions with surface-exposed functional groups such as amines, carboxyls, and thiols. These strategies typically utilize amine reactive chemistry or click chemistry-based conjugations [164, 165]. Noncovalent approaches are often conducted under mild reaction conditions, which help minimize structural damage and preserve the biological functionality of EVs. However, covalent modifications do not directly compromise the structural or functional integrity of EVs. However, the residual reactive components that remain after conjugation can potentially induce adverse biological effects, necessitating thorough purification [166]. Additionally, although surface engineering is a faster and simpler alternative to endogenous engineering, careful optimization of the reaction conditions is necessary to prevent nonspecific interactions between EVs and functional ligands and ensure the specificity and stability of conjugation. Exogenous engineering: membrane fusion Recent studies have reported the generation of hybrid vesicles by fusing EVs with other types of EVs derived from different cell sources or synthetic nanoparticles such as liposomes. Fusion is typically accomplished by increasing membrane fluidity through simple incubation, PEG-induced fusion, freeze–thaw cycles, or co-extrusion. The resulting hybrid vesicles retain the intrinsic properties and biological functionalities of the original vesicles. This enables synergistic therapeutic outcomes, including enhanced drug delivery efficiency, improved targeting specificity and increased therapeutic efficacy [167, 168]. These hybrid systems offer multifunctionality and complex therapeutic capabilities that are difficult to achieve through conventional drug loading or surface modification alone. Ultimately, this improves in vivo performance and therapeutic outcomes [169, 170]. However, to achieve the high yield and efficiency required for the production of hybrid vesicles, further investigations are needed to optimize critical parameters such as vesicle ratios, mixing conditions, fusion time, and temperature. In parallel, the development of standardized analytical methods to quantitatively assess fusion efficiency and functional integration as well as efforts to ensure reproducibility between batches are required [171, 172]. Extracellular vesicle engineering for advanced macrophage reprogramming Various cell-derived EVs have been reported to modulate macrophage phenotypes through their intrinsic functions [171, 172]. However, the intrinsic functions of EVs alone are insufficient for effective treatment of complex diseases, and additional functions are required [173, 174]. For example, EVs, which inherently possess only neuroprotective or tissue-regenerative functions, may have limited immunomodulatory functions [175]. Therefore, various engineering strategies to impart immunomodulatory functions to EVs have been recently developed to overcome these limitations [176, 177]. Cytokine-engineered extracellular vesicles Cytokines are key immunoregulatory factors that induce the polarization of macrophages and are involved in creating a pro-inflammatory or anti-inflammatory microenvironment, depending on the signal transmitted by the cytokine transmitted [178]. As mentioned above, pro-inflammatory cytokines such as IFN-γ, TNF-α, IL-1, and IL-6 induce the release of inflammatory factors from macrophages by activating the JAK/STAT, MAPK, and NF-κB signaling pathways, thereby amplifying the inflammatory response [179, 180]. On the other hand, anti-inflammatory cytokines such as IL-10, TGF-β, IL-4, and IL-13 induce the expression of anti-inflammatory factors by upregulating pathways such as STAT3, SMAD2/3, PI3K/AKT, and STAT6, respectively, and promote differentiation into M2 macrophages, thereby suppressing the production of pro-inflammatory cytokines and alleviating the inflammatory response [181–183]. Based on these immunomodulatory properties, strategies for modulating macrophage polarity by loading anti-inflammatory cytokines into EVs or expressing them on their surface have recently been actively studied. IL4-sEVs were isolated after transfecting HEK293T cells with the pCMV-IL4-LA plasmid, which fuses the IL-4 and Lysosomal-associated membrane protein A genes. These IL4-sEVs suppressed the secretion of proinflammatory cytokines (iNOS, IL-1β, IL-6, TNF-α) through macrophage function modulation and increased the expression of anti-inflammatory cytokines (IL-10), inducing reprogramming from M1 macrophages to M2 macrophages, demonstrating high potential as an anti-inflammatory therapeutic [184]. Furthermore, IT-sMSC-exo derived from bone marrow-derived mesenchymal stem cells primed with IFN-γ and TNF-α were enriched in miR-7704, which exhibited potent anti-inflammatory effects in an acute lung injury (ALI) model. IT-sMSC-exo induced reprogramming of M1 macrophages to M2 macrophages, suppressed the expression of pro-inflammatory cytokines (IFN-γ, IL-6, TNF-α, IL-1β), and increased the expression of anti-inflammatory genes (CD206, Arg-1), thereby mitigating tissue damage [185]. These results suggest that cytokine-engineered EVs are attracting attention as next-generation immunotherapies that can induce the polarization conversion of immune cells and modulate the inflammatory microenvironment of diseases. Although anti-inflammatory cytokine-based EV strategies have been reported to date, which primarily induce polarization from M1 macrophages to M2 macrophages, future research utilizing pro-inflammatory cytokines to repolarize M2 macrophages to M1 macrophages is expected to be a promising approach in the field of immunooncology. Nucleic acid-engineered extracellular vesicles Beyond their primary function of storing and transmitting genetic information, nucleic acids also serve as central regulators of diverse biological processes, including immune cell development, differentiation, activation, migration, and polarization [186]. In particular, RNA molecules such as miRNA, siRNA, and mRNA have been reported to precisely regulate the gene expression network of immune cells and play a crucial role in macrophage function and polarization [187–189]. Based on these mechanistic characteristics, strategies for loading RNA into EVs or genetically engineering them for surface expression have recently been actively studied recently [190]. RNA engineering is gaining attention as an immunomodulatory technology that enhances the in vivo stability of RNA-based therapeutics and modulates their polarization by selectively delivering them to target immune cells and macrophages. This strategy enables modulation of the pathophysiology of various immune-related diseases, including inflammatory diseases, infections, autoimmune diseases, and cancer. MQ + Exo miR-130, which loaded miR-130a into tumor-derived exosomes derived from breast cancer cells, was delivered to macrophages and inhibited PPARγ, thereby increasing the expression of M1 markers (CD86, Irf5, Nos2, TNF-α, IL-1β) and decreasing the expression of M2 markers (CD206, Ym1, Arg, TGF-β, IL-10), thereby inducing repolarization of M2 macrophages into M1 macrophages. This effectively suppresses the invasiveness and migration of breast cancer cells and activates an anti-tumor immune response in the tumor microenvironment [191]. In addition, trypsin-treated FA-D27-tEV-miR-138 loaded with miR-138 simultaneously targeted GBM tumors and TAMs. These EVs induced repolarization of TAMs from M2 macrophages to M1 macrophages, decreased the expression of anti-inflammatory factors (CD206), and increased the expression of inflammatory cytokines (IL-1β) and pro-tumor cytokines (TGF-β). This enhances the anti-tumor immune response within the tumor microenvironment and effectively suppresses GBM growth [192]. These studies demonstrate that EVs loaded with nucleic acids or engineered on their surfaces can be utilized as functional carriers to precisely regulate macrophage polarization and effectively control inflammatory and tumor immune responses. This suggests their potential as next-generation immunotherapeutic platforms that enable genetic-level immunomodulation. Despite the therapeutic potential of EVs developed through nucleic acid engineering, several limitations remain. These include low and inconsistent loading efficiency, instability of the nucleic acid cargo, and difficulties in reproducible mass production. Furthermore, the non-specific biodistribution and potential immunogenicity of exogenous nucleic acids raise safety concerns that must be carefully addressed. Peptide-engineered extracellular vesicles Peptides, composed of short amino acid sequences, are easy to synthesize and modify and offer the advantages of precise structural and functional design. These advantages make them highly promising as in vivo delivery vehicles [193–195]. In particular, peptides that target macrophages and directly influence macrophage polarization have been identified. Accordingly, strategies for repolarizing macrophages by engineering peptides on the EV surface are attracting attention as effective strategies for modulating the microenvironment [196–198]. These properties suggest that peptides can be functionally displayed on EVs to modulate macrophage polarization. For instance, GT-RGEV@CSFRi, an EV surface engineered with CSFRi peptides targeting TAMs, was selectively taken up by M2 macrophages within tumors and is subsequently activated in the Golgi apparatus, which induces ROS production and triggers immunogenic cell death (ICD). Simultaneously, it reprogrammed the M2 phenotype of TAMs to the M1 phenotype, significantly upregulating M1 markers such as IL-6, NOS2, IFN-γ, Cxcl1, Cxcl2, and TNF-α. GT-RGEV@CSFRi functions as a multifunctional theranostic platform responsive to the TME, inducing both TME reprogramming and ICD, thereby suppressing tumor growth in HNSCC [199]. These findings highlight peptide-engineered EVs as a promising strategy for the effective regulation of macrophage polarization and immune activation within the TME. Accordingly, advancing the combination of disease-specific targeting peptides and EV cargo is essential for developing precise immunomodulatory applications. However, when peptides are conjugated to the EV surface, their binding to membrane proteins or lipid layers is often structurally unstable. Therefore, future studies should introduce covalent immobilization-based strategies or genetically engineered surface expression strategies to enhance the binding stability between peptides and the EV membrane, thereby ensuring consistent targeting efficiency and in vivo delivery precision. Polymer-engineered extracellular vesicles Polymers are characterized by their easily modifiable physicochemical properties, diverse structural variations, and easy surface modifications. Based on these characteristics, they can be utilized as in vivo drug delivery vehicles, and are attracting attention as potential carriers for enhancing drug delivery efficiency [200, 201]. In particular, the discovery of polymers that can selectively interact with receptors on the surface of macrophages indicates their potential to induce macrophage polarity switching. Accordingly, polymer engineered EVs are utilized as carriers to modulate the immune microenvironment [202, 203]. Polymer-based functional materials have also been used to enhance the immunoregulatory capacity of biologically derived nanocarriers such as exosomes. Exos-PH20 derived from HEK293T cells transfected with the PH20 gene, was chemically conjugated with folic acid (FA) on its surface to generate Exos-PH20-FA, which efficiently degrades high-molecular-weight hyaluronic acid (HA) within the TME. Exos-PH20-FA was shown to reprogram M2 macrophages into M1 macrophages, accompanied by increased expression of the pro-inflammatory cytokine IL-12 and decreased expression of the anti-inflammatory cytokine IL-10, thereby modulating the immune microenvironment and concurrently suppressing pulmonary metastasis of tumor cells [204]. Accordingly, polymer conjugation to exosomes has emerged as a precise immunotherapeutic delivery strategy designed to reconstruct the immune microenvironment and simultaneously improve therapeutic targeting specificity. However, polymer-engineered EVs have been developed to enhance stability, circulation time, and targeted delivery for macrophage reprogramming; however, several limitations remain. Synthetic polymers such as PEG or PLGA may induce immune responses or generate cytotoxic degradation products in vivo. In addition, polymer coating or conjugation can alter the native membrane structure of EVs, potentially reducing their intrinsic cell-interaction capacity and receptor-mediated uptake. The reproducibility of polymer coating and control over release kinetics also remain challenging, as variations in polymer density or crosslinking can lead to inconsistent biodistribution. Therefore, optimizing polymer composition, improving coating uniformity, and developing biocompatible, degradable polymers will be crucial for advancing the clinical translation of polymer-engineered EV therapeutics. Liposomes-extracellular vesicles hybridization via membrane fusion Liposomes are biocompatible carriers composed of phospholipid bilayers that reliably encapsulate therapeutic agents and control their release. They also offer the advantage of tunable physicochemical properties for specific therapeutic purposes [205]. In addition, it has been utilized as a platform for immune cell regulation because surface functionalization can enhance properties such as cell specificity and modulation of immune cell responses [206]. Recently, liposome–EV hybrid systems have attracted increasing interest as they represent a strategy that integrates the respective advantages of both nanoparticles, including biocompatibility, immune evasion, and target specificity [207]. Liposome-EV hybrids have been shown to be effective delivery vehicles for reprogramming immunosuppressive M2 macrophages into M1 macrophages in the tumor microenvironment, and their therapeutic efficacy based on immune microenvironment modulation has recently been demonstrated in several tumor and inflammatory disease models. miR497/TP-HENPs, hybrid nanoparticles co-loaded with triptolide and miR-497, overcome drug resistance in ovarian cancer and effectively modulate the immune microenvironment. The platform induced ROS production in tumor tissues and reprogrammed M2 macrophages into M1 macrophages, thereby increasing TNF-α expression and suppressing TGF-β1 expression. Furthermore, it effectively induced an anti-cancer immune response by increasing the proportion of M1 macrophages (F4/80⁺CD86⁺) and decreasing the proportion of M2 macrophages (F4/80⁺CD206⁺) [170]. The synergistic efficacy of this hybrid system arises from coordinated delivery of triptolide (ROS induction) and miR-497 (genetic reprogramming), where chemical-induced inflammatory priming enhances genetic-level macrophage reprogramming toward M1 phenotype. These liposome-EV hybrid nanoparticles induce the functional transformation of immune cells and restructure the cytokine network within the tumor microenvironment, thereby overcoming the limitations of existing drug treatments and suggesting new possibilities for immune-based anticancer treatments. Future advancements in nanoparticle design and control technologies are needed to expand the scope of application to various cancers and inflammatory diseases and to enhance therapeutic efficacy and safety. However, despite these promising results, several challenges remain for the clinical translation of liposome–EV hybrid therapeutics. The fusion process between liposomes and EVs often produces heterogeneous vesicle populations with variable size, composition, and surface charge, resulting in inconsistent therapeutic performance. In addition, excessive incorporation of liposomal lipids may disrupt the native membrane structure of EVs and alter receptor–ligand interactions that are essential for targeted macrophage uptake. Furthermore, the reproducibility of large-scale preparation and the long-term stability of hybrid vesicles remain to be optimized. Therefore, future efforts should focus on improving fusion uniformity, maintaining membrane integrity, and establishing standardized production protocols to ensure consistent and safe therapeutic outcomes. Biomaterial-based extracellular vesicles delivery platforms for macrophage reprogramming Many studies have demonstrated that the macrophage repolarization capacity, either derived from the intrinsic properties of EVs or enhanced through engineering, represents an effective therapeutic approach for various diseases that require modulation of the inflammatory microenvironment. However, systemically administered EVs may be delivered inefficiently to target cells and are subjected to rapid clearance by the mononuclear phagocytic system, particularly in the liver, spleen, and lungs (Fig. 3) [208]. Recently, increasing attention has been directed towards the development of advanced delivery platforms employing nanomaterials to overcome these limitations. These platforms have shown promising results in enhancing the stability of EVs and enabling their controlled release in response to specific physiological cues such as temperature, pH, and enzymatic activity, thereby improving therapeutic efficacy (Table 4). Biomaterial-based platforms can be engineered to selectively release EVs in tissues where the regulation of inflammation by macrophages is critical. This minimizes non-specific immune responses and enables more precise and efficient induction of macrophage polarization [209, 210]. Table 4Biomaterial-based EV delivery platforms for macrophage reprogramming and therapeutic applicationsDelivery platformPlatform compositionEV sourceEffect of delivery platformDiseaseRef.HydrogelDecellularized extracellular matrixMesenchymal stromal cells- More pronounced shift from M1 to M2 macrophage markers in the DSCM@EVs group compared to the free-exo group- Reduced collagen deposition and GFAP astrocyte counts in the DSCM@EVs group- Improved microenvironment for axon regeneration and increased neural signal density in the DSCM@EVs groupSpinal cord injury [211]Silk fibroinLPS-trained bone marrow-derived MSCs- Effective repolarization from M1 macrophages to M2 macrophages by silk hydrogel containing EVs- Reduced collagen deposition and improved microenvironment for tissue regeneration, supporting axonal growth and repair- Superior therapeutic efficacy of hydrogel-based EV delivery compared to free-exo, attributed to sustained release and localized bioactivitySkin wound healing and alveolar bone defect [212]Thermosensitive polymerAdipose-derived stem cells- More pronounced shift from M1 to M2 macrophage markers in the Exo-CD47block@CS group compared to the free-exo group- Reduced inflammatory infiltration, preserved peri-implant bone structure, and improved bone-implant contact in the Exo-CD47block@CS group, indicating superior therapeutic efficacy for peri-implantitis treatmentPeri-implantitis [213]Dual-physical-crosslinkingHuman foreskin mesenchymal stem cells- Enhanced M1-to-M2 macrophage polarization compared to the free-exo group, indicating effective immunomodulation by FSMSC-EV-loaded hydrogel- Reduced collagen deposition and improved wound microenvironment relative to free-exo group, promoting tissue remodeling and angiogenesis- Superior therapeutic efficacy of FM-EV@PSiW delivery over free-exo, enabling sustained EV release and accelerated diabetic wound healingDiabetic chronic wounds [214]Gelatin methacryloylIL-4–overexpressing NIH-3T3 fibroblasts- Enhanced M1-to-M2 macrophage polarization by GelMA/ExosIL−4 compared tohe free-exo group- Accelerated re-epithelialization and increased angiogenesis in diabetic wounds relative to the free-exo group- Superior therapeutic efficacy achieved by GelMa-ExosIL−4 hydrogel through sustained delivery and localized immune modulationDiabetic chronic wounds [215]ScaffoldCollagenUmbilical cord-derived mesenchymal stem cells- Enhanced M1-to-M2 macrophage polarization by CS/Exos scaffold compared to the free-exo group- Reduced collagen deposition and improved microenvironment for endometrial regeneration relative to thecontrol- Restoration of endometrial structure and fertility through increased hormone receptor expression and functional restorationIntrauterine adhesion [216]Collagen spongeTrichostatin A pretreated bone marrow mesenchymal stem cells- Enhanced polarization of M1 to M2 macrophages in the T Exo/Col scaffold group compared to the unmodified free-Exo group- Reduced collagen deposition, improved wound healing, and increased angiogenesis in the T Exo/Col scaffold group compared to the control group- Promotion of wound closure and tissue remodeling through scaffold-based T Exo deliverySkin wound healing [217]Acellular cartilage matrixM2 macrophages- More pronounced shift from M1 to M2 macrophage markers in the M2D-Exo/ACECM group compared to the free-exo group- Reduced collagen deposition and creation of a more supportive microenvironment for osteochondral regeneration in the M2D-Exo/ACECM group relative to the free-exo group- Superior osteochondral matrix signal density (e.g., collagen II, aggrecan) and reduced expression of fibrotic and hypertrophic markers in the M2D-Exo/ACECM groupArticular cartilage regeneration [218]Acellular cardiacCardiac adipose tissue-derived MSC- More pronounced M1-to-M2 macrophage polarization in the EV-enriched scaffold group compared to the free-exo group- Enhanced cardiac remodeling and tissue regeneration through reduced ventricular fibrosis and collagen deposition- Improved cardiac function and systemic immune microenvironment through scaffold-based MSC-EV treatmentMyocardial infarction (MI) [219]NanofibrousM2 macrophage- Enhanced repolarization from M1 to M2 macrophages in the PP-Exo scaffold group compared to the free-Exo group- Reduced fibrotic capsular thickness and created a microenvironment favorable for vascular and bone regeneration in the PP-Exo group compared to the free-Exo group- Enhanced angiogenesis–osteoclastogenesis–osteogenesis coupling, demonstrating superior bone tissue remodeling and regulation of the foreign body response in the PP-Exo scaffold groupBone regeneration [220, 221]MicroneedleHydrolyzed collagenBone marrow mesenchymal stem cells- More effective shift from M1 to M2 macrophage phenotype in the CMCSMN/Exos group compared to the free-exo group- Greater reduction in inflammatory cell infiltration and a more favorable microenvironment for mucosal tissue regeneration in the CMCSMN/Exos group- Accelerated wound healing and improved re-epithelialization, demonstrating superior therapeutic efficacy of the CMCSMN/Exos microneedle patchOral mucosal lesions [221]Porous gelatin methacryloylMesenchymal stem cells- A more prominent shift from M1 to M2 macrophage markers in the MN-MSC group compared to the free-exo group- Greater reduction in glial scar formation and a more supportive microenvironment for axonal regeneration in the MN-MSC group- Enhanced neuroregeneration and motor function recovery, demonstrating superior therapeutic efficacy of the MN-MSC microneedle patchSevere spinal cord injury [222]Chondroitin sulfate CHuman adipose stem cell- More prominent shift from M1 to M2 macrophage markers in the EV@cMN group compared to the free-exo group- A greater reduction in synovial inflammation and collagen deposition, and a more supportive microenvironment for joint tissue repair in the EV@cMN group- Improved cartilage protection and reduced bone erosion, demonstrating superior therapeutic efficacy of the EV@cMN microneedle system in rheumatoid arthritis treatmentRheumatoid arthritis [223]Polypeptide–DNA hydrogelHair follicle stem cells under hypoxia- More prominent shift from M1 to M2 macrophage markers in the P-DNA gel MNs group compared to the free-exo group- Greater reduction in collagen deposition and inflammatory response, with a more supportive microenvironment for wound healing in the P-DNA gel MNs group- Enhanced angiogenesis and accelerated re-epithelialization, demonstrating superior therapeutic efficacy of the P-DNA gel MNs microneedle patch in diabetic wound regenerationDiabetic ulcer wounds [224] Table 4Biomaterial-based EV delivery platforms for macrophage reprogramming and therapeutic applicationsDelivery platformPlatform compositionEV sourceEffect of delivery platformDiseaseRef.HydrogelDecellularized extracellular matrixMesenchymal stromal cells- More pronounced shift from M1 to M2 macrophage markers in the DSCM@EVs group compared to the free-exo group- Reduced collagen deposition and GFAP astrocyte counts in the DSCM@EVs group- Improved microenvironment for axon regeneration and increased neural signal density in the DSCM@EVs groupSpinal cord injury [211]Silk fibroinLPS-trained bone marrow-derived MSCs- Effective repolarization from M1 macrophages to M2 macrophages by silk hydrogel containing EVs- Reduced collagen deposition and improved microenvironment for tissue regeneration, supporting axonal growth and repair- Superior therapeutic efficacy of hydrogel-based EV delivery compared to free-exo, attributed to sustained release and localized bioactivitySkin wound healing and alveolar bone defect [212]Thermosensitive polymerAdipose-derived stem cells- More pronounced shift from M1 to M2 macrophage markers in the Exo-CD47block@CS group compared to the free-exo group- Reduced inflammatory infiltration, preserved peri-implant bone structure, and improved bone-implant contact in the Exo-CD47block@CS group, indicating superior therapeutic efficacy for peri-implantitis treatmentPeri-implantitis [213]Dual-physical-crosslinkingHuman foreskin mesenchymal stem cells- Enhanced M1-to-M2 macrophage polarization compared to the free-exo group, indicating effective immunomodulation by FSMSC-EV-loaded hydrogel- Reduced collagen deposition and improved wound microenvironment relative to free-exo group, promoting tissue remodeling and angiogenesis- Superior therapeutic efficacy of FM-EV@PSiW delivery over free-exo, enabling sustained EV release and accelerated diabetic wound healingDiabetic chronic wounds [214]Gelatin methacryloylIL-4–overexpressing NIH-3T3 fibroblasts- Enhanced M1-to-M2 macrophage polarization by GelMA/ExosIL−4 compared tohe free-exo group- Accelerated re-epithelialization and increased angiogenesis in diabetic wounds relative to the free-exo group- Superior therapeutic efficacy achieved by GelMa-ExosIL−4 hydrogel through sustained delivery and localized immune modulationDiabetic chronic wounds [215]ScaffoldCollagenUmbilical cord-derived mesenchymal stem cells- Enhanced M1-to-M2 macrophage polarization by CS/Exos scaffold compared to the free-exo group- Reduced collagen deposition and improved microenvironment for endometrial regeneration relative to thecontrol- Restoration of endometrial structure and fertility through increased hormone receptor expression and functional restorationIntrauterine adhesion [216]Collagen spongeTrichostatin A pretreated bone marrow mesenchymal stem cells- Enhanced polarization of M1 to M2 macrophages in the T Exo/Col scaffold group compared to the unmodified free-Exo group- Reduced collagen deposition, improved wound healing, and increased angiogenesis in the T Exo/Col scaffold group compared to the control group- Promotion of wound closure and tissue remodeling through scaffold-based T Exo deliverySkin wound healing [217]Acellular cartilage matrixM2 macrophages- More pronounced shift from M1 to M2 macrophage markers in the M2D-Exo/ACECM group compared to the free-exo group- Reduced collagen deposition and creation of a more supportive microenvironment for osteochondral regeneration in the M2D-Exo/ACECM group relative to the free-exo group- Superior osteochondral matrix signal density (e.g., collagen II, aggrecan) and reduced expression of fibrotic and hypertrophic markers in the M2D-Exo/ACECM groupArticular cartilage regeneration [218]Acellular cardiacCardiac adipose tissue-derived MSC- More pronounced M1-to-M2 macrophage polarization in the EV-enriched scaffold group compared to the free-exo group- Enhanced cardiac remodeling and tissue regeneration through reduced ventricular fibrosis and collagen deposition- Improved cardiac function and systemic immune microenvironment through scaffold-based MSC-EV treatmentMyocardial infarction (MI) [219]NanofibrousM2 macrophage- Enhanced repolarization from M1 to M2 macrophages in the PP-Exo scaffold group compared to the free-Exo group- Reduced fibrotic capsular thickness and created a microenvironment favorable for vascular and bone regeneration in the PP-Exo group compared to the free-Exo group- Enhanced angiogenesis–osteoclastogenesis–osteogenesis coupling, demonstrating superior bone tissue remodeling and regulation of the foreign body response in the PP-Exo scaffold groupBone regeneration [220, 221]MicroneedleHydrolyzed collagenBone marrow mesenchymal stem cells- More effective shift from M1 to M2 macrophage phenotype in the CMCSMN/Exos group compared to the free-exo group- Greater reduction in inflammatory cell infiltration and a more favorable microenvironment for mucosal tissue regeneration in the CMCSMN/Exos group- Accelerated wound healing and improved re-epithelialization, demonstrating superior therapeutic efficacy of the CMCSMN/Exos microneedle patchOral mucosal lesions [221]Porous gelatin methacryloylMesenchymal stem cells- A more prominent shift from M1 to M2 macrophage markers in the MN-MSC group compared to the free-exo group- Greater reduction in glial scar formation and a more supportive microenvironment for axonal regeneration in the MN-MSC group- Enhanced neuroregeneration and motor function recovery, demonstrating superior therapeutic efficacy of the MN-MSC microneedle patchSevere spinal cord injury [222]Chondroitin sulfate CHuman adipose stem cell- More prominent shift from M1 to M2 macrophage markers in the EV@cMN group compared to the free-exo group- A greater reduction in synovial inflammation and collagen deposition, and a more supportive microenvironment for joint tissue repair in the EV@cMN group- Improved cartilage protection and reduced bone erosion, demonstrating superior therapeutic efficacy of the EV@cMN microneedle system in rheumatoid arthritis treatmentRheumatoid arthritis [223]Polypeptide–DNA hydrogelHair follicle stem cells under hypoxia- More prominent shift from M1 to M2 macrophage markers in the P-DNA gel MNs group compared to the free-exo group- Greater reduction in collagen deposition and inflammatory response, with a more supportive microenvironment for wound healing in the P-DNA gel MNs group- Enhanced angiogenesis and accelerated re-epithelialization, demonstrating superior therapeutic efficacy of the P-DNA gel MNs microneedle patch in diabetic wound regenerationDiabetic ulcer wounds [224] Biomaterial-based EV delivery platforms for macrophage reprogramming and therapeutic applications - More pronounced shift from M1 to M2 macrophage markers in the DSCM@EVs group compared to the free-exo group - Reduced collagen deposition and GFAP astrocyte counts in the DSCM@EVs group - Improved microenvironment for axon regeneration and increased neural signal density in the DSCM@EVs group - Effective repolarization from M1 macrophages to M2 macrophages by silk hydrogel containing EVs - Reduced collagen deposition and improved microenvironment for tissue regeneration, supporting axonal growth and repair - Superior therapeutic efficacy of hydrogel-based EV delivery compared to free-exo, attributed to sustained release and localized bioactivity - More pronounced shift from M1 to M2 macrophage markers in the Exo-CD47block@CS group compared to the free-exo group - Reduced inflammatory infiltration, preserved peri-implant bone structure, and improved bone-implant contact in the Exo-CD47block@CS group, indicating superior therapeutic efficacy for peri-implantitis treatment - Enhanced M1-to-M2 macrophage polarization compared to the free-exo group, indicating effective immunomodulation by FSMSC-EV-loaded hydrogel - Reduced collagen deposition and improved wound microenvironment relative to free-exo group, promoting tissue remodeling and angiogenesis - Superior therapeutic efficacy of FM-EV@PSiW delivery over free-exo, enabling sustained EV release and accelerated diabetic wound healing - Enhanced M1-to-M2 macrophage polarization by GelMA/ExosIL−4 compared tohe free-exo group - Accelerated re-epithelialization and increased angiogenesis in diabetic wounds relative to the free-exo group - Superior therapeutic efficacy achieved by GelMa-ExosIL−4 hydrogel through sustained delivery and localized immune modulation - Enhanced M1-to-M2 macrophage polarization by CS/Exos scaffold compared to the free-exo group - Reduced collagen deposition and improved microenvironment for endometrial regeneration relative to thecontrol - Restoration of endometrial structure and fertility through increased hormone receptor expression and functional restoration - Enhanced polarization of M1 to M2 macrophages in the T Exo/Col scaffold group compared to the unmodified free-Exo group - Reduced collagen deposition, improved wound healing, and increased angiogenesis in the T Exo/Col scaffold group compared to the control group - Promotion of wound closure and tissue remodeling through scaffold-based T Exo delivery - More pronounced shift from M1 to M2 macrophage markers in the M2D-Exo/ACECM group compared to the free-exo group - Reduced collagen deposition and creation of a more supportive microenvironment for osteochondral regeneration in the M2D-Exo/ACECM group relative to the free-exo group - Superior osteochondral matrix signal density (e.g., collagen II, aggrecan) and reduced expression of fibrotic and hypertrophic markers in the M2D-Exo/ACECM group - More pronounced M1-to-M2 macrophage polarization in the EV-enriched scaffold group compared to the free-exo group - Enhanced cardiac remodeling and tissue regeneration through reduced ventricular fibrosis and collagen deposition - Improved cardiac function and systemic immune microenvironment through scaffold-based MSC-EV treatment - Enhanced repolarization from M1 to M2 macrophages in the PP-Exo scaffold group compared to the free-Exo group - Reduced fibrotic capsular thickness and created a microenvironment favorable for vascular and bone regeneration in the PP-Exo group compared to the free-Exo group - Enhanced angiogenesis–osteoclastogenesis–osteogenesis coupling, demonstrating superior bone tissue remodeling and regulation of the foreign body response in the PP-Exo scaffold group - More effective shift from M1 to M2 macrophage phenotype in the CMCSMN/Exos group compared to the free-exo group - Greater reduction in inflammatory cell infiltration and a more favorable microenvironment for mucosal tissue regeneration in the CMCSMN/Exos group - Accelerated wound healing and improved re-epithelialization, demonstrating superior therapeutic efficacy of the CMCSMN/Exos microneedle patch - A more prominent shift from M1 to M2 macrophage markers in the MN-MSC group compared to the free-exo group - Greater reduction in glial scar formation and a more supportive microenvironment for axonal regeneration in the MN-MSC group - Enhanced neuroregeneration and motor function recovery, demonstrating superior therapeutic efficacy of the MN-MSC microneedle patch - More prominent shift from M1 to M2 macrophage markers in the EV@cMN group compared to the free-exo group - A greater reduction in synovial inflammation and collagen deposition, and a more supportive microenvironment for joint tissue repair in the EV@cMN group - Improved cartilage protection and reduced bone erosion, demonstrating superior therapeutic efficacy of the EV@cMN microneedle system in rheumatoid arthritis treatment - More prominent shift from M1 to M2 macrophage markers in the P-DNA gel MNs group compared to the free-exo group - Greater reduction in collagen deposition and inflammatory response, with a more supportive microenvironment for wound healing in the P-DNA gel MNs group - Enhanced angiogenesis and accelerated re-epithelialization, demonstrating superior therapeutic efficacy of the P-DNA gel MNs microneedle patch in diabetic wound regeneration Hydrogel-mediated delivery systems Hydrogels are three-dimensional hydrophilic polymer networks that closely mimic the structural and biochemical properties of extracellular matrix and native tissues. This enables the hydrogels to exhibit excellent biocompatibility. These properties have enabled hydrogels to be widely used in drug delivery, tissue engineering, and regenerative medicine [209, 210]. The porosity and mechanical strength of hydrogels are critical for stable loading and delivery of EVs. Their porous structure effectively encapsulates and protects the exosomes, and their mechanical strength ensures structural stability in physiological environments. This enables the sustained release of exosomes, thereby enhancing their therapeutic efficacy [225]. These properties have been used to incorporate EVs into hydrogels and enhance their therapeutic efficacy in inflammation-related disease models. For instance, Exogel, a hydrolytically degradable PEG-based hydrogel, was engineered to regulate the release of EVs derived from M2-polarized bone marrow-derived macrophages by adjusting the crosslinking density and composition. This maintains a high local concentration, which is necessary for the phenotypic repolarization from M1 to M2. Exogel maintained concentrations of exosomes that were approximately 9.21-fold higher at the injection site than that for the free-Exo group, and sustained Arg-1 expression for up to six days. This effectively promotes wound healing through prolonged localized delivery [226]. In another study, a chitosan-graft-aniline tetramer (CS-AT)-based hydrogel loaded with human adipose-derived mesenchymal stem cell-derived exosomes, which promote M2 macrophage polarization, was constructed to create CS-AT-Exo. CS-AT-Exos exhibited excellent biocompatibility and enabled sustained, stable release of exosomes. This significantly enhanced IL-10 expression in RAW264.7 cells compared to the free-Exo group. Thus, CS-AT-Exos demonstrated the potential to effectively promote diabetic wound healing [227]. Hydrogels have additional features such as responsiveness to stimuli and precise tunability of their mechanical and chemical properties. These features provide hydrogels with high potential as effective multifunctional platforms for exosome delivery [228, 229]. A thermoresponsive F127-HA hydrogel was created by integrating the biocompatible polymer Pluronic F-127 with the natural biopolymer HA. It undergoes gelation at body temperature, enabling the sustained release of chondrocyte-derived EVs that can promote M2 macrophage differentiation at the implantation site. Compared to the control group, the Exo@Gel group significantly inhibited M1 polarization of macrophages induced by LPS treatment and demonstrated higher efficiency in reducing pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) while increasing the anti-inflammatory cytokine IL-10. This promoted polarization to the M2 phenotype, demonstrating the effectiveness of the hydrogel in treating OA through enhanced anti-inflammatory effects [209]. Additionally, an MMP-9 responsive hydrogel, loaded with M2-macrophage exosomes (M2-Exo) formed MRH@Exo, demonstrating strategic diabetic wound healing through release modulation based on the inflammatory phase. In the late inflammatory phase, where MMP-9 levels were significantly increased, MRH-Exo increased CD206 expression in macrophages compared to the free-Exo group and significantly reduced CD86 expression, effectively reprogramming M1 macrophages to M2 macrophages and thereby modulating the inflammatory microenvironment [210]. Similarly, an ROS/glucose dual-responsive hydrogel containing adipose-derived stem cell (ADSCs) exosomes that responded to high levels of ROS and hyperglycemia in diabetic wound environments enabled on-demand exosome release in a type 1 diabetes mouse model. The hydrogel was found to reduce the expression of M1 markers (IL-1β, IL-6, and TNF-α) in skin tissue and increase the proportion of CD163 + M2 macrophages. This promotes tissue repair and enhances the healing of diabetic wounds [230]. Overall, hydrogel-based exosome delivery systems are precise delivery platforms that maintain the structural stability and biological activity of EVs, while regulating their release in response to various physiological stimuli. Functional hydrogels that specifically respond to various physiological signals, such as enzymes, pH, ROS, and hyperglycemia, enable the efficient delivery of EVs to target macrophages. Additionally, hydrogels not only function as delivery systems, but also possess inherent therapeutic effects depending on their type and structure [227, 231]. Therefore, hydrogel-based platforms can utilize synergistic therapeutic strategies for the treatment of various diseases. However, several limitations exist, including release heterogeneity, loss of EV bioactivity during encapsulation, restricted diffusion through dense matrices, and reproducibility issues To address these limitations, controlling the degradation rate of hydrogel networks can help regulate EV release more precisely, as the expansion of the network’s pores during degradation enhances EV mobility. Additionally, predictive modeling for peptide-based hydrogel design is essential in identifying materials that preserve the bioactivity of sEVs and enable efficient delivery [232]. Developing and researching disease-specific materials is essential for advancing precise EV delivery platforms. Scaffold-mediated delivery systems Scaffolds are three-dimensional structures that support cell and tissue regeneration. They serve as biomaterial platforms capable of performing various functions, including sustained and localized delivery of drugs or biological factors and continuous release and modulation of the immune microenvironment [233]. Recently, the strategy of combining EVs with scaffolds to modulate macrophage polarization has gained attention. This approach simultaneously induces tissue regeneration and modulates the immune microenvironment [219, 234]. EVs face challenges in systemic circulationas they are rapidly eliminated or fail to reach the target tissues. However, when immobilized on scaffolds, they can offer advantages in terms of delivery efficiency, persistence, and localization of biological effects [21, 218]. In particular, scaffolds can be designed not only as simple delivery vehicles, but also as sustained release systems, immune cell reprogramming environments, tissue regeneration-promoting structures, and mechanical stimulation systems. Through integration with EVs, scaffolds have evolved into platforms capable of precisely modulating immune cell functions. Therefore, various scaffold-based strategies have been proposed to maximize the therapeutic efficacy of EVs. Among them, target-sustained release scaffolds, designed to effectively immobilize EVs at the lesion site and release them slowly, are gaining attention as one of the most fundamental and widely used approaches [216, 235]. The collagen/chitosan-based 3D-CC scaffold, which was fabricated using low-temperature 3D printing and loaded with exosomes derived from IGF-1 pre-treated neural stem cells, showed a cumulative exosome release rate of approximately 73.84% over 14 d. This system has demonstrated significant improvements in the recovery of neurological function in an animal model of TBI. Notably, the expression of M1 markers, including CD68 and Iba-1, decreased at the injury site and M1 macrophage activity was suppressed. Simultaneously, the expression of neural regeneration markers such as neuronal nuclei and myelin basic protein increased. This leads to the effective modulation of the immune microenvironment and promotes neural tissue repair [236]. In addition to EV delivery, immune microenvironment-regulating smart scaffolds, designed not only to precisely control immune cell functions but also to regulate inflammatory cytokines, miRNAs, immune modulators, and other factors, are gaining attention. A composite scaffold loaded with exosomes containing si-TNF-α in a core-sheath structure 3D bioprinted scaffold demonstrated a release rate of over 80% of siRNA-EVs within 48 h and suppressed TNF-α expression by 63%. This platform decreased the expression of M1 markers such as iNOS and CD86, increased the expression of M2 markers such as CD206 and Arg-1, induced approximately 90% wound closure, and enhanced angiogenesis in wound models, thereby acting as an effective strategy for immune microenvironment modulation and tissue regeneration [237]. A composite dual-layer hydrogel scaffold with ROS scavenging and immune modulation capabilities loaded with exosomes derived from bone marrow-derived stem cells demonstrated regenerative effects through antioxidant and immune microenvironment regulation at the cartilage defect site. The Exo@BH scaffold showed a cumulative exosome release rate of 72.3% over 7 days, and the expression of M1 markers such as iNOS and IL-6 decreased, whereas that of M2 markers such as CD206 and Arg-1 increased at the injury site. As a result, inflammation was suppressed and the expression of cartilage regeneration markers, such as COL2 and SRY-box transcription factor 9, was promoted, leading to effective cartilage tissue recovery [238]. In conclusion, scaffold-based EVs delivery systems are evolving beyond passive material carriers into intelligent therapeutic platforms that promote tissue regeneration and actively modulate the immune microenvironment. Precise modification of the physical structure and biochemical functionalities of the scaffold enables the regulation of the local concentration and release rate of EVs, thereby facilitating the activation of diverse immunomodulatory mechanisms. Recently, targeted sustained-release and immunomodulatory smart scaffolds have demonstrated significant therapeutic effects in various tissue damage models, establishing themselves as key platforms for next-generation immunoregenerative therapies. Future advancements are expected to combine the enhanced targeting capabilities of EVs, optimization of scaffold microstructures, and personalized immune response induction, leading to the development of personalized immune therapeutic technologies. Microneedle-mediated delivery systems Microneedles are fine needle structures ranging from tens to hundreds of micrometers in length that can be minimally invasively inserted into the skin or tissues, enabling the precise local delivery of drugs, genes, and bioactive molecules [239]. Moreover, microneedle-based delivery technology is gaining attention owing to its advantages over traditional injection methods such as reduced pain, improved drug bioavailability, and the ability for repeated or quantitative administration [240]. Strategies for inducing tissue regeneration and regulating the immune microenvironment by loading EVs onto microneedles have been actively studied. This approach enhances the retention of EVs within tissues and offers new possibilities for precision immunomodulatory therapies, including macrophage polarization. GelMA-MN@3D-Exo is a platform in which exosomes derived from MSC cultured in 3D (3D-Exo) are loaded onto a gelatin methacryloyl (GelMA) hydrogel-based microneedle patch (GelMA-MN), which is locally applied to spinal cord injury and effectively controls tissue regeneration and inflammatory responses through continuous release. GelMA-MN@3D-Exo has been confirmed to contribute to spinal cord tissue recovery by inhibiting the expression of TNF-α, IL-1β, which are pro-inflammatory markers, and increasing the expression of IL-10, which is an anti-inflammatory marker [241]. The MEs@PMN platform encapsulated M2 macrophage-derived exosomes in microneedles and incorporated polydopamine nanoparticles into the backing layer. It is designed to deliver exosomes to the dermis and enhance wound healing through photothermal effects induced by near-infrared irradiation. MEs@PMNs combined with NIR achieved a cumulative exosome release rate of 84% and a 5% reduction in wound size. Reprogramming M1 macrophages to the M2 macrophages by decreasing the expression of TNF-α, IFN-γ, IL-6, iNOS and increasing the expression of CD206, Arg-1, IL-10, confirmed the regulation of inflammation [242]. In conclusion, the microneedle-based EVs delivery strategy represents an effective approach for promoting tissue regeneration and modulating the immune microenvironment by enabling the precise, minimally invasive delivery of EVs to target tissues. Notably, this platform enhances the therapeutic efficiency by improving the stability and tissue retention of EVs. The combination of various functional components, such as thermotherapy or hydrogel integration, can further enhance therapeutic efficacy. These composite platforms present new possibilities for the treatment of chronic diseases such as refractory wounds and nerve damage. However, several translational challenges remain. The stability of EVs during microneedle fabrication, the precise control of release kinetics, and the limited tissue penetration efficiency can restrict therapeutic consistency and reproducibility. Recent studies suggest that optimizing microneedle composition, employing biocompatible fabrication conditions, and developing multi-layered or porous microneedle structures may help preserve EV bioactivity and enable sustained, deep tissue delivery [243–245]. Acknowledging and addressing these issues will be critical for advancing microneedle-based EV platforms toward clinical translation. Clinical applications of extracellular vesicles-based macrophage reprogramming EVs possess characteristics such as low immunogenicity, minimal cytotoxicity, and excellent biocompatibility, which support their suitability as a new therapeutic platform for clinical applications [27, 57]. In addition, for commercialization as a therapeutic agent, it is essential to evaluate and verify its safety, efficacy, immunogenicity, and pharmacokinetics in patients. Discussing the current research and development trends is critical for advancing the clinical application of EVs. Preclinical studies demonstrating Immunomodulatory effects EVs with macrophage-reprogramming capabilities have been extensively used in various preclinical models, including tumors, inflammatory diseases, and autoimmune diseases. OX40L M1EV, exosomes from M1-like macrophages overexpressing OX40L, have been demonstrated to reduce the proportion of tumor-infiltrating M2-like macrophages and inhibit tumor growth in a mouse breast cancer model [102]. MSC-derived EVHypo cultured under hypoxic conditions modulated the M1/M2 macrophage balance and alleviated inflammation in a skeletal muscle injury model, demonstrating that EVHypo can promote muscle regeneration [55]. sEVs derived from RAW264.7, with suppressed tyrosine-protein phosphatase non-receptor type 1 expression, attenuated intestinal inflammation by inducing macrophage polarization toward the M2 phenotype in an LPS-induced inflammatory bowel disease model [246]. In addition to the therapeutic efficacy of unengineered EVs, engineered EVs have demonstrated therapeutic potential in preclinical studies. sEVCurAc, curcumin-loaded milk-derived sEV, reduced fibrosis and necrosis in a CCl4-induced acute liver disease model [157]. FA-GDEVs, derived from GDEVs, effectively accumulated in the joint area in a collagen-induced arthritis mouse model, reducing the number of M1 macrophages and increasing the number of M2 macrophages, thereby alleviating the pathological changes in rheumatoid arthritis and demonstrating therapeutic effects. In particular, FA has been demonstrated to target M1 macrophages and selectively accumulate in the joint area, thereby providing an efficient treatment [146]. Based on these studies, efforts are being made to translate disease treatment strategies involving macrophage reprogramming using EVs into clinical applications. Immunomodulatory approaches in current clinical applications The complexity of the human body and differences between patients make it difficult to directly apply preclinical results in clinical settings. Therefore, it is important to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of EVs systematically. This validates preclinical findings and aids the development of optimal treatment strategies. Clinical studies are also necessary to assess the complex reactions in the human body and patient characteristics that cannot be observed in preclinical models. Thus, clinical research is essential for the commercialization and regulatory approval of EV-based therapeutics. Several clinical studies have been conducted to verify the therapeutic effects of regulating macrophage polarization using EVs. Cell-free cord blood-derived MSC EVs (CF-CB-MSC-EVs) were administered to patients with chronic kidney disease stage III–IV CKD and demonstrated their ability to suppress inflammatory immune responses and improve kidney function. Immune modulatory markers, such as TGF-β and IL-10, peaked at week 12. On the other hand, the level of TNF-α consistently decreased until the end of the study, demonstrating the immunomodulatory efficacy of CF-CB-MSCs-EV [247]. Another clinical study using MSC-derived EV was conducted in patients with steroid-resistant graft-versus-host disease (GvHD). When MSC-derived EV were administered to patients, it suppressed the secretion of major inflammatory cytokines, such as TNF-α and IFN-γ, in peripheral blood mononuclear cells (PBMC), while increasing the secretion of IL-10. Through this immune modulation, the study demonstrated an improvement in GvHD symptoms for more than 4 months [248]. Additionally, a clinical trial registered in the ClinicalTrials.gov database (NCT05375604) provides an overview of the clinical application of EVs for disease treatment through macrophage reprogramming, as well as the current progress of ongoing research. The trial involved nine patients with advanced hepatocellular carcinoma and liver metastases originating from primary gastric or colorectal cancer. It was designed to induce the reprogramming of macrophages from the M2 to the M1 phenotype to induce anti-tumor effects. The trial involved the intravenous administration of CDK-004, an exosome derived from cells loaded with a STAT6 antisense oligonucleotide. This trial aimed to evaluate the safety, pharmacokinetics, and dose adjustment in a phase 1 clinical study. However, the trial is still ongoing. This study is the only clinical trial targeting macrophage reprogramming using EVs, suggesting that clinical research related to the macrophage-modulating abilities of EVs is still in its early stages of development. In addition, most current EV-related clinical studies are focused on wound healing, cancer treatment, and regenerative medicine, demonstrating growing clinical interest in EV-based therapies. Nevertheless, challenges such as large-scale GMP manufacturing, product heterogeneity, and regulatory uncertainty still hinder the clinical commercialization of EV-based therapies. Key challenges and perspectives for clinical advancement Despite promising preclinical efficacy, the clinical translation of EV-based macrophage reprogramming faces significant challenges. A prime example is the halting of MSC-EV clinical trials (NCT05881668, NCT05787288) due to manufacturing instability and the inability to mass-produce. These cases highlight significant barriers threatening the clinical translation of EV-based macrophage reprogramming therapies. These challenges, such as manufacturing inconsistencies, quality control deficiencies, and unpredictable biodistribution, directly impede the clinical advancement of EV-mediated macrophage reprogramming therapies and represent critical challenges that must be overcome. Further basic research and standardized clinical trial designs are necessary to facilitate additional trials. To advance the clinical applications of EVs, it is essential to verify their safety and efficacy, as well as aspects such as drug administration routes, dosage, and immunogenicity. First, a systematic study of the administration routes and in vivo distribution characteristics of EVs is necessary to establish an optimal delivery strategy and develop disease- and patient-specific therapies. EVs can be administered via various routes, including intravenous, intraperitoneal, or oral administration. Generally, nano-sized EVs accumulate primarily in organs with high blood flow, such as the liver, lungs, and kidneys [249, 250]. However, preclinical results have shown that different administration routes can deliver EVs more effectively to the desired tissues or organs, thereby enhancing their therapeutic effects [93, 95]. Furthermore, EVs engineered with HA have been shown to stabilize in the bloodstream and extend their circulation time [98]. Second, standardization of the dose and frequency of administration is necessary. Verification through staged clinical trials is essential for determining the optimal dose and dosing regimen based on individual patient differences and disease conditions. In preclinical studies, administration of 30 µg and 100 µg of human umbilical cord-derived mesenchymal stem cell-derived microvesicles or EVs in an acute kidney injury animal model promoted the dedifferentiation of renal tubular cells and alleviated kidney tissue damage. Similar levels of renal function recovery and histological improvement were observed at both doses [251, 252]. However, in a more advanced ischemia-reperfusion injury model, the 100 µg EV dose demonstrated superior therapeutic effects compared to the 30 µg dose [253]. This suggests that the dose of EVs can induce differential effects, depending on the pathological conditions of the disease. Because EVs are systemically distributed and exhibit nonlinear pharmacokinetic properties, simple dose conversion based on quantitative measurements may be limited in clinical applications. In particular, interspecies differences, the heterogeneity of EV composition, and the limited understanding of in vivo absorption pathways complicate clinical dose design. Therefore, for the clinical application of EV-based therapies, a dose-setting strategy that integrates cargo characteristics, pharmacokinetic indicators, and in vivo distribution based on the administration route is required. Accordingly, a standardized dose–response protocol should be established [254]. Third, basic research on toxicity assessment and immune responses is essential to confirm immunogenicity and ensure the potential for immune memory formation with repeated administrations. Strategies such as CD47 expression and MHC-I removal have been proposed to mitigate this, but clinical data on their long-term safety remain limited. Therefore, a systematic analysis of immune response triggers, along with precise evaluation of antibody generation and cytokine changes during repeated administration, must be included in clinical trial designs [255]. Safety of EVs is important for clinical transit. Immunogenicity is influenced by various factors, including cell origin, surface proteins, internal cargo, manufacturing and storage methods, dosage, and administration routes. Notably, allogeneic or xenogeneic-derived EVs are more readily recognized by the innate and adaptive immune systems than autologous-derived EVs, and there is an ion of EVs. A quantitative evaluation system for long-term immune response changes due to repeated administration is required in addition to immunological safety. Although most preclinical and early clinical studies have shown that EVs are safe, comprehensive data on dose-dependent immune responses, tissue-specific accumulation, and potential immune activation are lacking. In particular, differences in immune recognition and pharmacokinetics may arise depending on the administration route and speed, which can influence not only the therapeutic efficacy but also the occurrence of side effects. Therefore, future clinical trials must include long-term tracking of immune response markers, such as anti-EV antibodies and inflammatory cytokine panels, along with repeated administration models under various conditions. These strategies provide reliable evidence for the immunological safety of EV-based therapeutics [256]. Finally, the analysis of the components that drive the efficacy of EVs is crucial for understanding their mechanisms of action in clinical applications. Basic component analyses such as proteomic analysis and miRNA profiling are essential for predicting the therapeutic efficacy and safety of EVs. These analyses also enable standardization of clinical trial designs and therapeutic applications [106, 146]. In particular, miRNAs, a major functional cargo of EVs, play a key role in determining the targeting ability and reproducibility of the therapeutic effects. Engineering EVs as delivery vehicles for miRNAs allows for the quantitative control of the concentration of specific miRNAs, which is advantageous for standardizing therapeutic efficacy and customizing applications. Exogenous loading, based on its high loading efficiency and ability to regulate cargo, is suitable for clinical applications. Quantification based on the copy number of the loaded miRNAs can be used for potency assays and quality control standards. These analyses provide scientific evidence to elucidate the mechanism of action, evaluate the clinical efficacy, and establish regulatory approval criteria for EV-based therapeutics [257]. Conclusions and outlook Various cell-derived EVs reprogram macrophages by delivering biomolecules with immunomodulatory functions to reshape the immune environment and restore balance between pathological conditions. Macrophage-derived EVs have excellent capabilities in various immunomodulatory fields and are promising biomaterials with outstanding potential for applications in immunotherapy. Engineering strategies for EVs by loading or displaying therapeutic molecules, such as nucleic acids, peptides, and proteins, enable targeted and synergistic treatments for diseases. In addition, EV delivery platforms using hydrogels, scaffolds, and microneedles have enabled local delivery and improved therapeutic efficacy. Therefore, customized EVs engineered with a combination of disease-specific selection of the EV origin and selection of materials with desired features are effective immunotherapy strategies for various diseases, including immune disorders and cancer. Further precise mechanistic studies required for the advancement of EV application may provide answers to the dual function of one type of EV in promoting or inhibiting the growth of a particular tumor. In addition, studies should be conducted to minimize the adverse effects and predict its effectiveness against various diseases. Validation of factors such as EV immunogenicity, biodistribution, and circulation time and establishment of standardized production and quality control guidelines are also essential to drive the development of currently limited clinical applications. Their comprehensive study provides a promising potential for EVs to bring about a paradigm of next-generation precision treatment beyond conventional treatment methods and efficacy. Moreover, the therapeutic potential of EVs can be further enhanced through integration with existing treatments such as immune checkpoint inhibitors, chemotherapy, and radiotherapy. EVs can enhance the efficacy of checkpoint blockade and reduce resistance to immunotherapy by reprogramming macrophages and reshaping the immune microenvironment. Furthermore, engineered EVs can serve as carriers of chemotherapeutic agents or radiosensitizers, providing synergistic effects while minimizing systemic toxicity. These combination strategies demonstrate the versatility of EVs as a novel platform for precise and complex therapies in clinical settings. Despite these promising advances, several challenges remain before EV-based therapeutics can achieve widespread clinical application. Issues such as mass production, purification consistency, and reproducibility of EV bioactivity still limit regulatory approval and commercial application. Moreover, the variability between EV sources and disease environments can lead to unpredictable therapeutic outcomes, highlighting the need for more standardized and comparable studies. Addressing these challenges is crucial to fully realizing the therapeutic potential of EV-mediated macrophage reprogramming.